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Chapter 1
Atherosclerosis and atherothrombosis
Atherothrombotic complications, including acute myocardial infarction, stroke 
and peripheral arterial diseases, are a major cause of  morbidity and mortality in 
Western industrialized countries. 
Already in childhood changes occur in the vessel wall, such as thickening, reor-
ganization of  the tunica intima, collagenous matrix protein and the deposition 
of  lipids.1 The lesions may progress by migration of  smooth muscle cells from 
the media to the intima of  the vessel wall. These cells proliferate and synthesize 
several matrix components. Some of  the cells will go into apoptosis and form a 
necrotic core. The lesion is covered by a fibrous cap, which plays an important 
role in plaque stabilization. Rupture of  this fibrous cap allows contact between 
coagulation factors in the blood and the thrombogenic tissue factor expressed 
by macrophage foam cells. This triggers platelet activation and aggregation. One 
of  the main factors that initiates platelet aggregation and thrombus formation at 
sites of  lesions of  the endothelium is Von Willebrand Factor (VWF). 
Figure 1 Process of  atherosclerosis and thrombus formation in a blood vessel.
Von Willebrand factor
Von Willebrand Factor is a glycoprotein that is important for platelet adhesion 
and aggregation and acts as a bridging molecule between subendothelial collagen 
molecules and circulating platelets at the site of  vascular injury. Furthermore, it 
serves as a chaperon molecule for Factor VIII. 
VWF is synthesized in endothelial cells and megakaryocytes. A monomer of  
proVWF is synthesized in the endoplasmatic reticulum and forms dimers via di-
sulfide bonds.2 These dimers subsequently form multimers, which are stored in 
 
Fig 1 Process of atherosclerosis and thrombus formation in a blood vessel 
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Weibel-Palade bodies in the endothelial cells and α-granules of  platelets. A small 
fraction of  VWF is constitutively secreted into the circulation. Upon stimula-
tion, ultra large VWF (ULVWF) is secreted from the Weibel-Palade bodies and 
forms string-like structures that are attached to the endothelial cell.3, 4 Under 
conditions of  high shear stress, ULVWF strings are cleaved by the metallopro-
tease A disintegrin-like and metalloprotease with thrombospondin type-1 motifs 
13 (ADAMTS13) at the Tyr1605-Met1606 bond to form multimers of  a size that 
normally circulate. The cleavage of  multimers is important because ULVWF in 
the microvasculature are thrombogenic.
The plasma levels of  VWF are regulated by genetic and non-genetic factors. 
The most important genetic factor is ABO blood group. Individuals with blood 
group O have around 25% lower levels of  VWF than individuals with non-O 
blood group. 5, 6 In addition, several common single nucleotide polymorphisms 
(SNPs) in the VWF gene influence the levels of  VWF. For example, carriers of  
the minor G-allele of  the –1793 C/G polymorphism in the promotor region, 
have 20% higher VWF levels.7 The GG genotype was also associated with a 
higher risk of  coronary heart disease.8 Also other SNPs in VWF gene have been 
reported to determine VWF levels or the risk of  cardiovascular disease.9, 10 
VWF plasma levels are also influenced by a large number of  non-genetic 
factors. Age is strongly associated with plasma levels of  VWF.11, 12 The 
rigidity of  the arterial wall and thereby the increased pulse pressure may 
stimulate VWF secretion. VWF levels are elevated in several inflammatory diseases, 
vasculitis and autoimmune diseases, which suggests that indeed cytokines and other 
markers of  inflammation induce the secretion of  VWF.13-15 Also in diabetic 
patients elevated levels of  VWF are found.16
ADAMTS13
The ADAMTS13 gene is located on chromosome 9q34. The gene is 
approximately 37 kb long and comprises 29 exons. The primary gene product is 
a protein of  1427 amino acids with a molecular mass of  145 kDa.
This VWF cleaving protease has been identified as the 13th member of  the 
ADAMTS family.  This family shares the homology of  domain structures. 
They all start with a signal peptide that is followed by a propeptide. The mature 
ADAMTS13 is build up by a catalytic domain, a disintegrin domain, TSP1-motif, 
a cystein-rich domain, a spacer domain, seven other TSP-1 domains and two 
CUB-domains. These two CUB-domains are specific for ADAMTS13 and are 
not seen in other members of  the ADAMTS family (Figure 2). The function 
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of  these domains is not completely known, but they may play a role in protein-
protein interactions.17
 
Figure 2 Domain alignment of  ADAMTS13
S: signal peptide, P:propeptide, TSP-1: thrombospondin-1 motif, CUB:complement compo-
nents C1r/C1s, Uegf  (epidermal growth factor) bone morphogenic protein-1
The expression of  ADAMTS13 has been observed in various cell types and 
tissues. The transcript of  approximately 4.7 kb is primarily expressed in the stel-
late cells in the liver.18, 19 It has been suggested that the stellate cells may play a 
role in the regulation of  plasma levels of  ADAMTS13.20 A transcript of  2.4 kb 
was detectable in multiple tissues, including placenta, skeletal muscle and certain 
tumor cell lines.18, 21-23 Also vascular endothelial cells have been shown to syn-
thesize and secrete ADAMTS13.24, 25 The expression of  ADAMTS13 has also 
been observed in platelets.26 Upon activation, ADAMTS13 may be released from 
platelets. It has been reported that ADAMTS13 is also expressed in renal tissue 
in glomeruli and tubuli.27
After initiation of  hemostasis platelets adhere to ULVWF, which is anchored 
to the activated endothelial cell or the exposed subendothelium. Shear stress 
forces and the binding of  the platelet receptor Glycoprotein Ibα to the A1 do-
main of  VWF cause a conformational change of  VWF. Hereby the ADAMTS13 
binding site and the scissile bond in the A2 domain in VWF become exposed. 
ADAMTS13 from the circulation binds to the A3 domain, which has been 
identified as the major docking site for the metalloprotease. Subsequently, the 
metalloprotease binds to the A2 domain. Once attached, ADAMTS13 cleaves 
VWF at the Tyr1605-Met1606 peptide bond, predominantly at or close to the 
anchoring sites of  the ULVWF multimers, where the tensile forces are the great-
est.28 The remaining strings of  VWF that are released after cleavage are less 
biologically active and less susceptible for cleavage.29 Hereby, the proteolysis of  
VWF by ADAMTS13 appears to be critical in preventing thrombosis in the 
microvasculature (Figure 3).
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Figure 3 Cleavage of  VWF by ADAMTS13 in a normal subject and a TTP patient (NEJM 2002 
Moake). Upon stimulation unusually large VWF multimers are released from the Weibel Palade 
bodies from the endothelial cell. ADAMTS13 (also known as VWF-cleaving protease) attaches to 
the endothelial cell via one of  its thrombospondin-1-like domains. It than cleaves the unusually 
large multimers into smaller multimers and prevents thereby that VWF can induce adhesion and 
aggregation of  platelets during normal flow.
Thrombotic Thrombocytopenic Purpura
The physiological importance of  ADAMTS13 is examplified by the rare 
disease entity thrombotic thrombocytopenic purpura (TTP). In TTP,  ADAMTS13 
activity is strongly reduced or absent which results in the inability to cleave 
ULVWF into smaller fragments. This results in platelet aggregation and 
eventually in micro-vascular thrombus formation (Figure 3).
TTP is, if  untreated, a life-threatening disorder, which is characterized by throm-
bocytopenia, micro-angiopathic hemolytic anemia, neurological symptoms, 
renal dysfunction and fever. Typical for TTP is the occurrence of  microvascular 
hyaline thrombi in organs such as the brain and kidneys. These thrombi are 
VWF- and platelet-rich, but fibrin-poor. Platelets are consumed which leads 
to severe thrombocytopenia and thereby to hemorrhage, ischemia and organ 
dysfunction. 
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TTP can occur in two forms: a congenital form and an acquired form. The 
congenital form is caused by mutations in the ADAMTS13 gene, resulting in 
absence of  ADAMTS13 activity, while the acquired form is caused by the 
formation of  auto-antibodies against the metalloprotease.18, 30, 31 Most of  the 
auto-antibodies are inhibitory, but also non-inhibitory antibodies have been 
described. These are suggested to interfere with the binding of  ADAMTS13 to 
VWF or to accelerate the clearance of  ADAMTS13, which results in low levels 
of  ADAMTS13 in plasma.
ADAMTS13 in other diseases
Decreased levels of  ADAMTS13 have also been reported in several other 
disease states including disseminated intravascular coagulation (DIC), sepsis, 
inflammatory diseases, in the post-operative state, hemolytic uremic syndrome 
(HUS) and liver disease.32-37
Sepsis and DIC are associated with a prothrombotic and systemic inflammatory 
state, in which many factors can influence ADAMTS13 activity. It is not known 
whether ADAMTS13 plays a role in inflammation, but studies have reported 
reduced ADAMTS13 activity in patients with acute systemic inflammation or 
sepsis.38-40 In sepsis plasma levels of  acute phase proteins, such as VWF are 
strongly increased. It has been suggested that the release of  VWF is so strongly 
increased that ADAMTS13 is no longer able to cleave all ULVWF molecules. 
Pro-inflammatory cytokines like Interleukin-8 (IL-8), tumor necrosis factor-α 
(TNF-α) and Interleukin-6 (IL-6) have been shown to have an effect on the 
release of  ULVWF and its processing.14 Chauhan et al. previously demonstrated 
that ADAMTS13 cleaves platelet-VWF strings, regulates platelet interaction and 
modulates the thrombotic response in injured arterioles.41, 42 These studies have 
shown that ADAMTS13 may be a new link between inflammation and throm-
bosis. This link is interesting, since inflammation is associated with a prothrom-
botic state43 and ADAMTS13 may be an intermediate or pathogenetic factor. In 
this thesis we will focus on the association between ADAMTS13 and cardiovas-
cular disease, such as acute myocardial infarction, transient ischemic attack and 
ischemic stroke. Furthermore, we will investigate ADAMTS13 in other disease 
states that are associated with a prothrombotic phenotype.
Genetics of  ADAMTS13
Since the discovery of  a genetic defect of  ADAMTS13 in patients with con-
genital TTP, genetic analyses have been performed in many patients, and various 
16
mutations in the ADAMTS13 gene have been reported. Often, carriers of  such 
mutations are known to develop TTP during childhood, but also cases with an 
adult onset have been reported.18 
Genetic variations occur throughout the ADAMTS13 gene without clustering. 
The majority of  the mutations are missense mutations, but also splice site, non-
sense and frame-shift mutations have been described.18, 44-53 
In recent years genetic variation in the ADAMTS13 gene has been further inves-
tigated. To date 46 mutations and 19 non-synonymous SNPs have been found 
in the ADAMTS13 gene.54  It is not completely clear whether these genetic 
variations influence the activity of  ADAMTS13. When the activity of  
ADAMTS13 activity is reduced by the genetic variation, this may result in larger 
VWF multimers. For example, in individuals with the P475S polymorphism, 
ADAMTS13 is normally secreted, but has a low proteolytic activity toward VWF.45 
This SNP is very common in Japanese subjects. Nearly 10% of  the population 
is heterozygous for this polymorphism, whereas P475S is rare in Chinese.55 The 
frequency in Caucasians is yet unknown. The ADAMTS13 variant Q449X is 
secreted normally, but is characterized by a very low activity of  ADAMTS13. 
Also combinations of  genetic variations may result in low ADAMTS13 activity.56
Some mutations that cause premature truncations have shown to impair secre-
tion or reduce ADAMTS13 activity. The frameshift mutation 4143-4144insA 
results in deletion of  the second CUB-domain and results in impaired 
ADAMTS13 secretion.44 Since some of  the polymorphisms are influencing the 
activity of  ADAMTS13 one can imagine that these polymorphisms may influ-
ence VWF levels and thereby the risk of  arterial thrombosis. 
In this thesis several single nucleotide polymorphisms (SNP) in ADAMTS13 
will be studied. The SNPs have been chosen according to the Seattle SNP site 
(http://pga.gs.washington.edu/ ). In this database, tools are provided to select 
certain tagging SNPs to cover the whole genetic variation in a gene of  inter-
est. The selected SNPs will be studied in relation to the levels and activity of  
ADAMTS13 and to the relative risk of  arterial thrombosis.
Assays for ADAMTS13
Since Furlan and Tsai reported the discovery of  ADAMTS13, several assays to 
determine ADAMTS13 activity or concentration have been developed.31, 57 The 
assays that measure ADAMTS13 activity are based on two principles: (1) detec-
tion of  VWF cleavage fragments or (2) VWF residual activity after cleavage by 
17
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ADAMTS13.58
The first described assay was the Gerritsen assay and was based on the 
principle of  proteolysis of  VWF by ADAMTS13 and quantifying the amount of  
VWF digestion products. A disadvantage of  this method is that it is very time- 
consuming and has a high coefficient of  variation.59
The cleavage products of  VWF can be detected by VWF multimer structure 
analysis under non-reducing conditions57 or SDS-PAGE under non-reducing 
conditions (140 kDa and 176 kDa)  or two site immuno-radiometric assays with 
antibodies against the C- and N-terminal VWF epitopes. Cleavage is detected by 
an apparent loss of  VWF antigen.60
A limitation of  these assays is that they are performed under static conditions. 
They require urea or guanidine HCL to denaturate and unfold VWF, which 
is time-consuming. Furthermore, Ba2+ or Ca2+ must be added to stimulate 
ADAMTS13 activity. 
Newer assays have become available for the measurement of  ADAMTS13. 
Some of  them use recombinant VWF fragments that do not need the denaturing 
conditions, such as the recombinant VWF A2 domain or the VWF73 
peptide. These assays are less complex and save time. The VWF73 peptide has 
been reported to be the minimal substrate to be recognized and cleaved by 
ADAMTS13.61
One more recent developed assay can detect cleavage products by 
immunoblotting, ELISA or fluorescence.62-65 Furthermore, another assay uses 
more physiological conditions and measures ADAMTS13 under flow and 
quantifies the amount of  ULVWF-platelet strings that are cleaved.29 This assay 
is reliable primarily for discriminating between levels of  ADAMTS13 higher or 
lower than 20%.66 As an alternative one can use the detection of  VWF residual 
activity after proteolysis of  VWF to measure ADAMTS13 activity. The VWF 
residual activity correlates with the multimeric size. The residual activity of  VWF 
can be determined by the ability of  VWF to bind to collagen or to induce platelet 
aggregation in the presence of  ristocetin.58, 59
 
Outline of  this thesis
The aim of  this thesis is to further unravel the physiological and 
pathophysiological role of  ADAMTS13 in several disease states. In the first part 
we will study ADAMTS13 in cardiovascular disease, with a special focus on the 
genetic variation in both ADAMTS13 and VWF. The second part of  the thesis 
studies the role of  ADAMTS13 in other pathological conditions known to be 
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associated with a prothrombotic state. In addition several assays for ADAMTS13 
antigen and activity levels are compared both in healthy controls and patients.
In chapter 2 a study on the relationship between ADAMTS13 and VWF in 
patients with ischemic stroke included in the COCOS study is presented. This 
study is previously described.67 We hypothesize that low levels of  ADAMTS13 
may result in higher VWF levels and thereby increase the risk of  arterial throm-
bosis. 
Subsequently another, independent study is performed in the ATTAC 
study population, a case-control study of  young patients who have recently 
suffered a first acute myocardial infarction, ischemic stroke or peripheral arterial 
disease. We include young individuals, males before the age of  45 and women 
before the age of  55, because it is known from previous studies that in younger 
patients the contribution of  genetic variation is more pronounced than in elderly 
subjects. The role of  genetic variation, its relationship with levels of  ADAMTS13 
and the risk of  arterial thrombosis are assessed (Chapter 3). The role of  genetic 
variation in ADAMTS13 is further investigated in Chapter 4, in which we study 
a genetic variant that is previously reported to be associated with a reduced 
activity of  ADAMTS13 in Japanese subjects. Genetic variations in VWF 
gene have been described that lead to less or increased cleavage of  VWF. We 
hypothesized that common SNPs in VWF gene maybe be associated with 
the risk of  arterial thrombosis by influencing the cleavage by ADAMTS13. 
Therefore, we study a genetic variant in the VWF gene that is previously 
reported to be associated with increased proteolysis of  VWF (Chapter 4b).68
The second part of  the thesis describes the role of  ADAMTS13 in other 
pathological conditions associated with microvascular thrombosis, such as 
liver cirrhosis (Chapter 5) and sepsis (Chapter 6). The liver is the main site of  
synthesis of  many coagulation factors. Also ADAMTS13 is synthesized in the liver 
predominantly in stellate cells. In patients with cirrhosis of  the liver several 
alterations of  the haemostatic system do occur.69 Most of  the coagulation 
factors are reduced in cirrhosis, mainly due to decreased synthesis. However, these 
alterations do not necessarily lead to a bleeding disorder, but are now even 
thought to be associated with a prothrombotic state.70 We study the role of  
ADAMTS13 and VWF in patients with liver cirrhosis to further unravel primary 
hemostasis in these individuals (Chapter 5). 
Another pathological condition in which we study the role of  ADAMTS13 
is meningococcal sepsis. Patients with sepsis often suffer from thrombotic 
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complications. Especially patients with meningococcal sepsis frequently have 
severe disseminated intravascular coagulation (DIC) and microthrombi forma-
tion, even resulting in limb ischemia and skin necrosis. Therefore we investigated 
the levels of  ADAMTS13 in children with meningococcal sepsis which were 
referred to our hospital to study its potential pathogenetic role in hemostatic 
complications and outcome of  these patients. (Chapter 6)
The last part of  this thesis comprises a study on various assays of  ADAMTS13 
that are currently available. Some of  the assays only measure activity of  
ADAMTS13 while others measure the antigen levels of  ADAMTS13. Initially 
these assays where designed for the diagnosis of  TTP. We will investigate the 
correlation between these assays in patients with TTP, but also in patients with 
liver cirrhosis. The results of  this study are reported in Chapter 7.
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Abstract 
Background
Elevated Von Willebrand Factor (VWF) concentrations are associated with 
an increased risk of  ischemic heart disease. Several factors influence VWF 
antigen levels and activity, including blood group, genetic variability, acute phase 
response and proteolysis by ADAMTS13, a determinant of  proteolytic cleavage 
of  VWF. We assessed how these factors affect the relationship between VWF 
and the occurrence of  stroke to understand the underlying mechanism.
Methods
In a case-control study in 124 first-ever ischemic stroke patients and 125 age 
and sex-matched controls we studied VWF antigen (VWF:Ag), VWF Ristocetin 
Cofactor activity (VWF:RCo),  ADAMTS13 activity,  the –1793C/G 
polymorphism in the VWF gene and C-Reactive Protein (CRP). 
Results
VWF antigen and activity levels were significantly higher in cases than controls. 
The relative risk of  ischemic stroke was the highest in individuals in the upper 
quartile of  VWF:Ag OR 2.8 (95% CI 1.2-6.4) and VWF:RCo OR 1.9 (95% CI 
0.9-4.3) compared with the individuals in the lowest quartiles. In individuals with 
ADAMTS13 in the lowest quartile the relative risk of  stroke was 1.6 (95% CI 
0.7-3.8) compared with individuals in the highest quartile. CRP, ADAMTS13 
and genetic variation did not affect the association between VWF and the 
relative risk of  stroke, whereas blood group did affect the association.
Conclusion
VWF antigen and activity are associated with the occurrence of  acute 
ischemic stroke. This relationship is not affected by the severity of  the acute phase 
response nor by genetic variation or degradation.
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Introduction
Von Willebrand Factor (VWF) is a plasma glycoprotein that is a mediator of  
platelet adhesion to the vascular subendothelial collagen, which becomes 
available when the endothelium is damaged. VWF is released as ultra-large 
multimers, which form spontaneous high-strength bonds with the platelet 
glycoprotein 1b-IX-V complex, resulting in platelet aggregation and thrombus 
formation.1 The concentration and activity of  VWF are influenced by several 
factors, including blood group, inflammation and proteolysis by ADAMTS13 
(A Disintegrin and Metalloprotease with ThromboSpondin motif). Genetic 
variations in the VWF gene are associated with VWF levels, for example the 
–1793 C/G polymorphism in the promotor region of  the VWF gene. The 
G-allele is associated with higher levels of  VWF antigen than the C-allele.2
Proteolysis by ADAMTS13 also determines VWF activity. ADAMTS13 is a 
recently discovered metalloprotease that specifically cleaves the bond between 
tyrosine 842 and methionine 843 in the A2 domain of  VWF multimers, resulting 
in 2 fragments of  176-kDa and 140-kDa.3, 4 These fragments are less active in 
platelet aggregation compared with the uncleaved Ultra Large VWF multimers 
(ULVWF).  A deficiency of  ADAMTS13 is seen in patients with thrombotic 
thrombocytopenic purpura (TTP), characterized by cerebral ischemia caused by 
platelet thrombosis in the cerebral microcirculation.5, 6 
Several studies have shown that high VWF antigen levels are a risk factor for 
arterial thrombosis.7-9 However, information on VWF and cerebrovascular 
disease is limited and not consistent.8, 10 We hypothesized that ADAMTS13 plays 
a role in arterial thrombosis, because reduced ADAMTS13 activity will result 
in less degradation of  ULVWF multimers and thereby in an increased VWF 
activity. The aim of  our study is to further investigate the role of  VWF in 
ischemic stroke and to assess how the factors mentioned above can affect the 
relationship between VWF and the occurrence of  ischemic stroke.
Methods
Study design
We performed a case-control study, where cases were consecutively recruited 
patients with first-ever acute ischemic stroke, admitted to the department of  
Neurology of  the Erasmus University Medical Center. Population controls were 
partners, friends or neighbours of  the patients. They were age-and sex matched, 
of  the Caucasian race, without a history of  stroke and not related to the patient. 
The study design has previously been described in more detail elsewhere.11 
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Plasma level measurements
Von Willebrand Factor antigen (VWF:Ag) was determined with an in-house 
ELISA assay using polyclonal rabbit antihuman VWF antibodies (DakoCytoma-
tion, Glostrop, Denmark). Von Willebrand Factor ristocetin cofactor activity 
(VWF:RCo) was measured by an aggregometric method using formaline-fixed 
platelets and ristocetin (Diagnostica Stago, Asnières, France). 
ADAMTS13 activity was measured using a rapid functional assay that deter-
mines the digestion of  VWF by ADAMTS13, based on the method described 
by Gerritsen with minor modifications as described before.12 Normal Pooled 
plasma (NPP) obtained from plasma of  40 healthy volunteers was used for cali-
bration.  
The concentration of  CRP was determined with a sensitive in-house enzyme 
immunoassay using rabbit antibodies against human CRP as catching antibodies 
and goat antibodies against human CRP as tagging antibodies (DAKO, Den-
mark).
-1793 C/G Polymorphism in Von Willebrand Factor gene
The DNA fragment containing the polymorphism was amplified by PCR with 
forward primer  5’AGCCCAGCGGACAGTGCGAG-3,  and reverse primer: 
5’ TACAAGAATGGGCAGTGCAG-3. The PCR comprised 4 min at 95°C of  
initial denaturation followed by 32 cycles of  1 min  at 94°C, 1 min at 65°C and 
2 min at 72°C. Subsequently the PCR product of  264 bp was digested by AciI, 
which cleaves the G-allele into 2 fragments of  180 and 84 bp, while the common 
C-allele was not cleaved. The fragments were separated using a 2% agarose gel 
and visualized using UV.13
Statistical analysis
The levels of  VWF:Ag, VWF:RCo and ADAMTS13 were compared in cases 
and controls and in subgroups regarding blood group  with a Student’s t-test. 
VWF:Ag, VWF:RCo and ADAMTS13 activity were divided into quartiles based 
on the distribution in the control group. The relationship between the levels 
of  these variables and ischemic stroke was estimated using logistic regression 
with the lowest quartile as reference, except for the ADAMTS13 activity where 
the highest quartile is the reference group. The analyses were adjusted for pos-
sible confounders such as blood group and vascular risk factors, adjustment for 
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age and sex was not performed because the controls and cases were matched 
for these variables. A p-value of  <0.05 was considered to indicate statistical 
significance. In the subgroup analysis for blood group, logistic regression was 
performed using quartiles of  VWF, which were calculated for each subgroup 
separately. Correlations were estimated using the Spearman correlation co- 
efficient.
The relationship between the levels of  VWF and the –1793 C/G polymorphism 
was studied with analysis of  variances (ANOVA) with adjustment for age, sex 
and blood group. The association of  the –1793 C/G polymorphism with the 
occurrence of  ischemic stroke was estimated by logistic regression and is 
presented with the 95% confidence intervals (CI). The statistical analysis was 
carried out using SPSS software version 11.
Results
The study included 124 patients and 125 sex- and age-matched controls and 
the characteristics are presented in Table 1. Plasma levels were available for all 
individuals. Genetic analysis could be performed for 109 patients and 119 
controls.
Table 1 Baseline characteristics 
Cases
(N=124)
Controls
(N=125)
P-value
Demographics
Age (y) 56 (±12) 56 (±12) n.s
Female sex 58 (47%) 59 (47%) n.s
Blood group
O 54 (44%) 63 (50%) 0.37
Non O 68 (56%) 62 (50%)
Risk factors
Smoking 61 (49%) 37 (30%) 0.004
Hypertension 60 (48%) 24 (19%) 0.000
Diabetes 18 (14%) 5 (4%) 0.004
Hypercholesterolemia 78 (61%) 84 (67%) 0.70
CRP 2.01 1.42 0.008
Data for age are presented as mean (±sd). Data for CRP are presented as median (25-75% 
range). Other data are counts (percentages). CRP= C-Reactive Protein.
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Table 2 Levels of  Von Willebrand Factor (VWF) and ADAMTS13 in cases and controls
Cases Controls p-value OR (95% CI)
VWF:Ag 1.47±0.66 1.23±0.50 0.002 2.2 (1.3-3.7)
VWF:RCo 1.37±0.74 1.13±0.47 0.002 1.9 (1.2- 3.0)
ADAMTS13 0.96±0.41 1.03±0.44 0.23 0.7 (0.4-1.4)
All levels are in U/ml and indicate mean (±sd). 
ORs (95% CI) per U/ml are adjusted for blood group.
P-values indicate the significance of  the t-test for the differences between cases and controls.
Table 3 Relationship between Von Willebrand Factor (VWF) levels, ADAMTS13 and stroke
Q1 Q2 Q3 Q4
VWF:Ag (U/ml)
OR (95% CI)
<0.84
1 (reference)
0.84-1.17
1.8 (0.8-4.0)
1.17-1.52
2.4 (1.0-5.5)
>1.52
3.2 (1.4-7.5)
VWF:RCo (U/ml)
OR (95% CI)
<0.78
1 (reference)
0.78-1.06
1.6 (0.7-3.4)
1.06-1.46
1.4 (0.7-3.2)
>1.46
2.1 (0.9-4.8)
ADAMTS13 (U/ml)
OR (95% CI)
<0.70
1.7 (0.71-3.9)
0.70-0.95
1.9 (0.9-4.3)
0.95-1.34
2.0 (0.9-4.5)
>1.34
1 (reference)
Given are the odds ratios for the quartiles with 95% CI and p-value, adjusted for blood group.
Table 4 Levels of  VWF and ADAMTS13 in individuals with blood group O versus non-O
Cases Controls
Blood
group O
Blood
group non-O
P Blood 
group O
Blood 
group non-O
P
VWF:Ag 1.30±0.62 1.59±0.66 0.017 1.00±0.39 1.47±0.50 <10-3
VWF:RCo 1.15±0.69 1.54±0.74 0.004 0.93±0.38 1.33±0.47 <10-3
ADAMTS13 0.96±0.41 0.97±0.41 0.89 1.11±0.44 0.95±0.43 0.06
Presented are VWF antigen and activity and ADAMTS13 in U/ml and indicate mean ±sd for the 
cases and controls and blood group O versus non O.
VWF:Ag= VWF antigen. VWF:Rco= VWF Ristocetin cofactor activity
VWF:Ag levels were significantly higher in the cases (mean ± sd, 1.47 U/ml 
±0.66) compared with the controls (1.23 U/ml ±0.50), p=0.002. Levels of  
VWF:RCo were also higher in the cases than in the controls (1.37 U/ml ± 0.74 
versus 1.13 U/ml ±0.47, p=0.002). The relative risk of  stroke (OR) for VWF:Ag 
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as a continuous variable was 2.20 (95% CI 1.3-3.7) (Table 2). Individuals with 
the highest levels of  VWF:Ag (highest quartile) had a significantly increased rela-
tive risk 3.21 (95% CI 1.4-7.5) compared to individuals in the lowest quartiles 
(Table 3). In the highest quartiles of  VWF:RCo the relative risk of  stroke was 
2.06 (95% CI 0.9-4.8).
As expected, lower levels of  VWF:Ag were found in all individuals with blood 
group O (1.14 U/ml ± 0.53) compared with individuals with blood group non-
O (1.53 U/ml ± 0.59). The levels of  VWF:RCo were also lower in individuals 
with blood group O compared with individuals with blood group non O. Within 
cases and controls higher levels were found in the ones with blood group non-O 
(Table 4).
The relative risk of  stroke in individuals increased with increasing VWF levels 
(p for trend 0.002) and in the highest quartile of  VWF:Ag with blood group O 
the relative risk was 5.9 (95% CI 1.6-21.5) while in subjects with blood group 
non O the relative risk was 1.6 (95% CI 0.5-5.2) (p for trend 0.69) (Figure 1).
Figure 1a Odds ratio for the quartiles of  VWF:Ag. The white bars represent blood group O 
(p for trend 0.002) and the black bars represent blood group non-O (p for trend 0.69).
Figure 1b Odds ratio for the quartiles of  ADAMTS13. The white bars represent blood group 
O and the black bars represent blood group non-O.
Levels of  ADAMTS13 were slightly, but not significantly, lower in the cases 
(0.96 U/ml ±0.41) than in the controls (1.03 U/ml ± 0.44, p=0.23). The OR 
for ADAMTS13 in the lowest quartile was 1.7 (95% CI 0.7-3.9) with the highest 
quartile as a reference group. 
A weak but significant correlation was found between ADAMTS13 and 
VWF:Ag (rs= -0.14, p=0.05) and VWF:RCo (rs= -0.18, p=0.01). Adjustment for 
ADAMTS13 had only a minor effect on the relationship between VWF 
parameters and stroke risk.
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Since it has been reported previously that individuals with blood group O had 
significantly higher levels of  ADAMTS13 we performed a subgroup analysis 
for blood group.14 The levels of  ADAMTS13 in the controls with blood group 
non-O were somewhat lower than in controls with blood group O (p=0.06) 
ADAMTS13 levels were similar in the various blood groups in the cases 
(Table 4). 
The median level of  CRP was 2.07 mg/l in the cases and 1.42 mg/l in the 
controls (p=0.11). Although CRP was significantly correlated with the levels of  
VWF:Ag (rs= 0.19), VWF:RCo (rs= 0.24) adjustment for CRP did not influence 
the relationship between these VWF parameters and stroke risk.
The allele distribution of  the polymorphism was in Hardy-Weinberg equilibrium. 
The frequency of  the minor allele of  the –1793 C/G polymorphism was 0.33 
(95% CI 0.3-0.4) in the cases and 0.30 (95% CI 0.24-0.36) in the controls (n.s). 
The levels of  VWF:Ag were slightly higher in the group with the GG-genotype 
in the cases (1.65± 0.56 U/ml) than in the other genotypes (1.52± 0.61  U/ml 
for the CC-genotype and 1.39 ± 0.60 for the CG-genotype) (p=0.41). In the 
patients with ischemic stroke with the GG-genotype we also observed higher 
levels of  VWF:RCo (1.64 U/ml ±0.56) than in patients with other genotypes 
(VWF:RCo in CC-genotype 1.47 U/ml ±0.86 and 1.23 U/ml ± 0.57) (p=0.11) 
in the CG-genotype. Similar, but weaker, trends were seen in controls (Table 5). 
The ORs for stroke were 0.9  (95% CI 0.5-1.5) in the CG genotype and 0.7 (95% 
CI 0.3-1.6) in the GG-genotype, with the CC genotype as reference.
Table 5 Relation between polymorphism VWF –1793C/G polymorphism and VWF levels in 
cases and controls
Cases
CC(n=52) CG(n=47) GG(n=10)
VWF:Ag 1.52±0.61 1.39±0.60 1.65±0.56 p=0.41
VWF:RCo 1.47±0.86 1.23±0.57 1.64±0.56 p=0.11
Controls
CC(n=51) CG(n=54) GG(n=14)
VWF:Ag 1.23±0.45 1.24±0.51 1.25±0.71 p=0.99
VWF:RCo 1.08±0.40 1.22±0.52 0.99±0.53 p=0.15
All levels are in U/ml and indicate mean ±sd. 
P-values calculated by comparing the genotypes in the group of  cases, idem for controls.
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Discussion
The present study shows a significant relationship between increased VWF:Ag 
levels and the occurrence of  ischemic stroke. A similar relationship was 
observed for VWF:RCo activity. In this study VWF levels were associated with 
genetic variation, ADAMTS13 activity, inflammation and blood group. 
However, after adjustment for these factors, the relationship between VWF and 
stroke remained similar.
It is well known that VWF levels are dependent upon ABO blood groups. 
Previously it has been reported that individuals with blood group non-O have 
higher levels of  VWF.15 It has been reported that individuals with blood group 
non-O also have a higher risk of  arterial thrombosis. 16, 17
We also observed higher VWF levels in blood group non-O individuals and 
therefore performed subgroup analysis for blood group. Interestingly, we found 
a higher relative risk of  stroke in individuals in the highest quartile of  VWF 
levels with blood group O OR 5.9 (95% CI 1.6-21.5) compared with individ-
uals in the highest quartile of  VWF levels with blood group non-O OR 1.6 
(95% CI 0.5-5.2). The underlying mechanism for this finding is not clear. Some 
mechanisms have been proposed through which blood group affects VWF, 
such as the clearance of  the VWF, which differs in the various blood groups 
due to varying carbohydrate structure of  plasma glycoproteins.18 Furthermore 
gene loci were suggested to have a quantitative effect on plasma levels of  VWF. 
ABO blood group locus is one of  these, located on chromosome 9q34. Since 
the gene is located very close to ADAMTS13 we investigated with HAPMAP 
(http://www.hapmap.org) if  there was any linkage disequilibrium, but the genes 
were in different Linkage Disequilibrium-blocks.
Inflammation is an important determinant of  VWF levels19 and it has therefore 
been suggested that raised VWF levels measured shortly after stroke are merely 
a marker of  the acute phase response rather than the cause of  the event. CRP 
and VWF levels were indeed correlated in our study. However, after adjusting 
for CRP, VWF levels remained significantly associated with the risk of  ischemic 
stroke. This indicates that inflammation may play a role in determining levels of  
VWF, but it will not be the only important regulatory mechanism since VWF 
levels are independently of  inflammation also associated with the relative risk of  
ischemic stroke. 
The -1793 C/G polymorphism in the promoter region of  the VWF gene is as-
sociated with VWF levels in plasma.2 We have previously shown that carriers of  
the G-allele have a significantly increased risk of  acute myocardial infarction.13 
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This indicates that genetic variation in the VWF gene, resulting in higher VWF 
levels, may be causally related with the relative risk of  arterial thrombosis. In 
the present study, the highest levels of  VWF (VWF:Ag and VWF:RCo) were 
also found in individuals with the GG- genotype (n.s.). However, there was no 
indication that carriers of  the G-allele have a higher relative risk of  ischemic 
stroke.
Proteolytic cleavage of  ULVWF by ADAMTS13 into less active 
smaller multimers determines the activity levels of  VWF in plasma. We therefore 
hypothesized that ADAMTS13 activity may be associated with the risk 
of  stroke. This is the first study that determines levels of  ADAMTS13 in 
patients with ischemic stroke and indeed we observed that levels of  ADAMTS13 
activity are somewhat lower in ischemic stroke patients compared with the 
controls. In individuals with the lowest levels of  ADAMTS13 the risk of  
ischemic stroke was almost doubled OR 1.6 (95% CI 0.7-3.8) compared to 
individuals in the highest quartile of  ADAMTS13 levels. However, these 
results were not statistically significant and these findings should be confirmed in 
studies with a larger patient population. Our study shows that the levels of  
VWF and ADAMTS13 are negatively associated, similar to what been found in a 
variety of  conditions in previous studies.14 Therefore we can only speculate 
about the underlying mechanism: low levels of  ADAMTS13 resulting in higher 
VWF levels, or an increase of  VWF levels resulting in lower ADAMTS13 levels. 
In addition, ADAMTS13 levels in our control group were also dependent upon 
blood group, individuals with blood group O having higher levels than non-O, 
as has been reported earlier.14, 20 This was not seen in our patient group, which 
may indicate that the increase in VWF levels found ischemic stroke patients, 
overrules the difference between in VWF due to blood group.  
In conclusion, this study shows clearly that high levels of  VWF antigen and 
VWF activity are associated with an increased risk of  stroke. Our results 
indicate that inflammation, genetic variation and degradation by ADAMTS13 
partly determine VWF levels, however we did not demonstrate an interaction 
with the effect of  VWF on ischemic stroke risk.
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Abstract
Background 
ADAMTS13 may play a role in arterial thrombosis by cleaving the highly 
active and thrombogenic ultralarge VWF multimers into less active VWF 
multimers. The aim was to investigate the relationship between plasma levels of  
ADAMTS13, VWF and genetic variation in the ADAMTS13 gene with cardio-
vascular disease.
Methods
We performed a case-control study in 374 patients with a first-ever arterial 
thrombosis before the age of  45 years in males and 55 years in women. We 
included 218 patients with coronary heart disease (CHD), 109 patients with 
ischemic stroke (IS) and 47 patients with peripheral arterial disease (PAD) and 
332 healthy population-based controls. ADAMTS13 and VWF levels were 
measured 1-3 months after the event.
Results
ADAMTS13 levels were associated with cardiovascular disease (OR antigen 5.1 
(95% CI 3.1-8.5, p <0.001) and OR activity 4.4 (95% CI 2.5-7.5, p< 0.001), in 
the lowest quartiles). VWF levels were associated with cardiovascular disease 
(OR antigen 2.1 (95% CI 1.3-3.3, p=0.001) and OR activity 2.0 (95% CI 1.3-
3.1, p=0.003), in the highest quartile). Patients with combined low ADAMTS13 
levels and high VWF levels had an odds ratio of  7.7 (95% CI 3.3-17.7) (p for 
trend <0.0001). No association was found between genetic variation in the 
ADAMTS13 gene with levels of  ADAMTS13 or with risk of  cardiovascular 
disease.
Conclusion
In conclusion, levels of  ADAMTS13 and VWF are strongly associated with the 
risk of  cardiovascular disease.  
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Introduction
Von Willebrand Factor (VWF) is a glycoprotein that has an important function 
in the haemostatic process. VWF binds the glycoprotein Ib-IX-V-complex on 
platelets, which stimulates platelet adhesion and aggregation. VWF is synthe-
sized in endothelial cells and stored in Weibel-Palade bodies, in which ultra large 
VWF multimers (ULVWF) are formed. These very active ULVWF multimers 
are released into the circulation upon stimulation of  the endothelium and easily 
form platelet aggregates. In the regulation of  the size of  the VWF multimers 
an important role is played by ADAMTS13 (A Disintegrin And Metalloprotease 
with ThromboSpondin motifs).1
ADAMTS13 is a metalloprotease that consists of  1427 amino acids and that 
cleaves the bond between amino acids Tyr1605 and Met1606 in the A2 domain 
of  VWF.2, 3 The ADAMTS13 gene contains 29 exons and is located on chromo-
some 9q34.1, 4 To date, little is known about the regulation of  ADAMTS13, but 
it is known that plasma levels of  ADAMTS13 are partially determined by genetic 
factors, since several amino acid variants have been described that correlate with 
ADAMTS13 activity.5, 6
Extremely low levels of  ADAMTS13 are seen in thrombotic thrombocytopenic 
purpura (TTP). TTP is characterized by intravascular platelet aggregation and 
microvascular thrombi, which can result in life threatening cerebral ischemia and 
arterial thrombosis.9  The antithrombotic role of  ADAMTS13 is also shown in 
less extreme situations, in animal studies and in-vitro studies.7, 8
Because of  this antithrombotic role, we hypothesized that low levels of  
ADAMTS13 will result in an increased risk of  cardiovascular disease. However, 
only limited, conflicting data are available on the role of  ADAMTS13 in the 
pathogenesis of  cardiovascular disease.10, 11
The genetic component in the pathogenesis of  cardiovascular disease is 
stronger in young patients than in elderly patients. In elderly patients, the contri-
bution of  the classical age-related cardiovascular risk factors is more important.12 
For this reason we studied the relationship between the genetic variation in the 
ADAMTS13 gene and the levels and risk of  cardiovascular disease in men 
before 45 years and women before 55 years old.
The aim of  this study was to investigate the relationship between ADAMTS13, 
VWF activity, the genetic variation in ADAMTS13 and the risk of  cardiovascular 
disease in young individuals.
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Patients and Methods
Study design
We performed a case-control study, in which cases were consecutive patients 
who presented with a first acute ischemic event in the Erasmus MC. Patients 
from the Erasmus MC were included if  they were 45 years or younger for males 
or 55 years or younger for females. In these age groups cardiovascular disease 
are rare (frequency 2% in the Netherlands)13 and genetic factors are known to 
play a larger role at young ages.12 The cohort consisted of  three subgroups: 
(i) coronary heart disease (CHD), containing patients with acute myocardial 
infarction (AMI) and unstable angina pectoris (UAP), (ii) Ischemic Stroke, 
containing patients with an ischemic stroke or transient ischemic attack (TIA), 
(iii) peripheral arterial diseases (PAD). We used population-based controls, i.e. 
neighbors or friends of  the patients, fulfilling the same age criteria and without a 
history of  cardiovascular diseases. The study was approved by the Medical 
Ethical Committee of  the Erasmus MC and written informed consent was 
obtained from all patients and controls.
Definitions
AMI was defined as typical chest pain, with elevated cardiac markers (CK, MB, 
troponin T) or characteristic electrocardiographic findings (ICD 410). UAP was 
defined as typical chest pain at rest (ICD 413). TIA was defined as suddenly 
occurring focal cerebral deficit, which could not be explained otherwise than 
by local cerebral ischemia (ICD 435). Symptoms had to be temporary and last 
less than 24 hours after onset. Ischemic Stroke (IS) was defined as suddenly 
occurring cerebral deficits, which could not be explained other than by local 
cerebral ischemia (ICD 434). Brain imaging by CT or MRI was compatible with 
the diagnosis. The diagnosis PAD was defined as peripheral arterial stenosis 
resulting in ischemia, classified according to the Rutherford criteria.14
Blood sampling 
Blood was collected 1-3 months after the event in citrate (0.105 M) using a 
Vacutainer System (Beckton-Dickson, Plymouth, UK). and centrifuged at 2000 
g for 10 min at 4˚C, followed by 10 min at 20,000 g for 10 min at 4˚C and 
plasma was stored in aliquots at -80˚C Genomic DNA was isolated according to 
standard salting-out procedures. DNA was available from 350 patients and 310 
controls due to logistic reasons. Technicians were not aware of  the case-control 
status of  the samples.
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Methods
ADAMTS13 activity and antigen were measured using the Technozym 
ADAMTS13 kit (Technoclone, Vienna, Austria) as described by the manu-
facturer. Fluoresence was measured at 360/460 nm (Biotek reader FLX 800, 
Austria). The intra-assay variation was 10% for ADAMTS13 activity and 18% 
for ADAMTS13 antigen. Levels in pooled plasma of  40 healthy men was 
defined as 100%
VWF antigen (VWF:Ag) was determined in duplicate with an in-house ELISA 
assay, using polyclonal rabbit anti-human VWF and horseradish peroxidase con-
jugated anti-human VWF (DakoCytomation, Glostrop, Denmark) for catching 
and tagging, respectively. VWF collagen binding (VWF:CB) was measured in 
duplicate by an in-house ELISA using type I collagen (Sigma, St Louis, USA) 
for catching and horseradish peroxidase conjugated anti-human VWF for 
tagging. The intra-assay variations of  VWF:Ag and VWF:CB were 14.5% and 
6.4% respectively.
Genotyping of  ADAMTS13
The haplotype-tagging SNPs (htSNP) in this study were selected based on the 
SeattleSNPs database (http://pga.gs.washington.edu/) (16468 (rs 2301612), 
19925 (rs 2073932), 25504 (rs 652600), 21576 (rs 603551)). We considered only 
SNPs with a minor allele frequency of  at least 5% in the Caucasian population 
(build 125, http://www.ncbi.nlm.nih.gov/SNP). 
Polymerase chain reaction (PCR) was performed using allele- 
specific Taqman analysis (Applied Biosystems, Foster City, USA). Haplostats 
(http://cran.r-project.org/src/contrib/Descriptions/haplo.stats.html) was used 
to compute maximum likelihood estimates of  haplotypes probabilities. Only the 
four haplotypes with a frequency >5% were included in the statistical analysis. 
The most frequent haplotype was used as reference. Genotypes with less then 10 
homozygotes for the minor allele are combined with the heterozygotes. 
Statistical analysis
The medians (25th-75th percentile) were presented because the levels are 
not normally distributed. The levels of  ADAMTS13 antigen, ADAMTS13 
activity, VWF:Ag and VWF:CB were compared in cases and controls and in the 
genotypes using an analysis of  variance (ANOVA) with adjustment for age and 
sex. Levels of  ADAMTS13 antigen, ADAMTS13 activity, VWF:Ag and VWF:CB 
were divided in quartiles based on the distribution in the control group. The 
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relationship between the levels of  these variables and the occurrence of  a cardio-
vascular event was determined using logistic regression, using the lowest quartile 
as reference, except for ADAMTS13, where the highest quartile constituted the 
reference. In the subgroup analysis, we used tertiles of  the distribution instead 
of  quartiles, because of  the small numbers of  patients. We adjusted for age, sex, 
smoking, hypertension, diabetes mellitus and hypercholesterolemia. 
The association between ADAMTS13 haplotypes and risk of  arterial 
thrombosis was determined by weighted logistic regression analysis using 
HaploStats software.15 Briefly, Haplotstats calculates the posterior probabilities 
for each possible haplotype of  an individual and assigns an appropriate weight 
to the risk estimate of  the corresponding haplotype. This statistical method 
increases the accuracy of  risk estimates that are calculated from phase- 
ambiguous genotype data. With a power calculation considering an α=0.05 and 
a β=0.80 and with the allele frequencies of  the SNPs, we calculated to find odds 
ratios between 1.2-2.4. A p-value of  <0.05, was considered to indicate statistical 
significance. All statistical analyses were two-sided and carried out using SPSS 
software version 12.
 
Results
The study included 374 patients and 332 controls.  As expected, we observed 
more risk factors, such as smoking, hypertension, diabetes and statin use in 
patients (Table 1).
The ADAMTS13 activity was significantly lower in cases 96.4% (70.3-112.2) 
than in controls 109.5% (93.0-123.8) (median (25th-75th percentile) (p<0.001)). 
ADAMTS13 antigen levels were also significantly lower in cases (78.6% (56.0-
102.3) than in controls 97.4% (81.7-111.1) (p<0.001). The specific activity 
of  ADAMTS13 (ratio activity to antigen) was higher in cases (1.11 (1.0-1.3) 
compared to controls (1.08 (0.9-1.2) p=0.01). Individuals with the lowest levels 
of  ADAMTS13 antigen and activity had increased relative risks OR 5.1 (95% CI 
3.1-8.5, p< 0.001, p<0.001*) and OR 4.4 (95% CI 2.5-7.5, p< 0.001, p<0.001*), 
respectively *(after Bonferroni correction) compared with the individuals in 
the highest quartile of  ADAMTS13. The individuals with the highest specific 
activity of  ADAMTS13 had the highest risk OR 1.9 (95% CI 1.2-3.2, p=0.012, 
p=0.048*) compared with individuals with the lowest ratio.
VWF:Ag levels were significantly higher in cases (1.20 (0.9-1.6) U/ml than in 
controls 1.04  (0.8-1.4) U/ml; p<0.001). Levels of  VWF:CB were also higher in
cases (1.32 (1.0-1.7) than in controls 1.16 (0.9-1.5) U/ml, p< 0.001. Individuals 
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Table 1 Baseline characteristics
Cases Controls P-value
Demographics
Age, yrs 42.8± 7.0 38.5 ± 8.0 <0.001
Male, n (%) 162 (43.3%) 122 (36.7%) 0.08
Body mass index, kg/m2 26.4 ± 4.6 25.1 ± 4.2 <0.001
Systolic blood pressure, mm Hg 128 ± 24 125 ± 17 0.09
Diastolic blood pressure, mm Hg 80 ± 14 80 ± 11 0.70
Index event
UAP/AMI 49/169
Stroke/TIA 52/57
PAD 47
Risk factors
Smoking (former+ current) (%) 297 (82%) 162 (51%) <0.0001
Hypertension or anti-hypertensive 
drugs
293 (78%) 62 (19%) <0.0001
Diabetes 33 (10%) 5 (2%) <0.0001
Medication
Betablockers 223 (60%) 7 (1%)
Diuretics 44 (12%) 6 (1%)
ACE inhibitors 150 (40%) 3 (1%)
Lipid lowering drugs 303 (81%) 2 (0.6%)
Clopidogrel 184 (49%) 0 (0%)
with levels of  VWF:Ag and VWF:CB in the highest quartile had an increased risk 
OR 2.1 (95% CI 1.3-3.3, p=0.001, p=0.004*) and 2.0 (95% CI 1.3-3.1, p=0.003, 
p=0.012*), respectively) compared with individuals in the lowest quartiles 
(Table 2).
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Table 2 Relationship between levels of  VWF, ADAMTS13 and risk on cardiovascular disease
Q1 Q2 Q3 Q4
VWF:Ag (U/ml) <0.8 0.9-1.0 1.1-1.4 > 1.5
OR (95% CI) 1 (reference) 1.1 (0.7-1.1) 1.4 (0.9-2.2) 2.1 (1.3-3.3)
VWF:CB act (U/ml) <0.9 1.0-1.2 1.3-1.5 > 1.6
OR (95% CI) 1 (reference) 0.9 (0.5-1.4) 1.4 (0.9-2.1) 2.0 (1.3-3.1)
ADAMTS13 antigen 
(% of  NPP)
<81.6 81.7-97.3 97.4-111.0 > 111.1
OR (95% CI) 5.1 (3.1-8.5) 2.2 (1.3-3.9) 2.1 (1.3-3.7) 1 (reference)
ADAMTS13 activity 
(% of  NPP)
<93.0 93.1-109.5 109.6-123.8 > 123.9
OR (95% CI) 4.4 (2.5-7.5) 2.3 (1.3-4.0) 1.8 (1.0-3.2) 1 (reference)
Values presented are the ORs for quartiles with 95% CI and P values, adjusted for age and sex.
Figure 1 The relation between ADAMTS13, VWF and cardiovascular disease. Individuals who 
were both in the highest tertile of  ADAMTS13 and in the lowest tertile of  VWF were used as 
reference.* p<0.05;** p<0.001
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We specifically assessed the risk of  cardiovascular disease in the individuals with 
both high levels of  VWF and low levels of  ADAMTS13 (Figure 1). These have 
a very high risk of  cardiovascular disease (OR 7.7, 95% CI 3.3-17.7) compared 
to individuals with low VWF levels and high levels of  ADAMTS13 (P for trend 
< 0.001, p<0.001*)(Figure 1)
Subgroup analysis
The decrease in ADAMTS13 levels was most clearly observed in the CHD 
subgroup. The median levels of  ADAMTS13 activity in the CHD group were 
significantly lower compared to controls; 88.54% (56.5-106.3) vs. 109.5% 
(93-123.8) p<0.001. In addition, ADAMTS13 antigen levels were lower in 
the CHD group 74.5% (50.6-98.2) than in the controls 97.38% (81.7-111.0), 
p<0.001. The specific activity of  ADAMTS13 was significantly higher in the 
CHD (1.1 (0.9-1.3) group compared to the controls (1.08 (0.9-1.2) p=0.002. In 
the other subgroups, the differences between cases and controls were smaller 
and not significant.
Individuals in the lowest tertile for ADAMTS13 antigen have an eight times 
increased risk for CHD compared with individuals in the highest tertile 
(OR 8.2, 95% CI 4.5-14.7 p< 0.001, p<0.001*). Individuals in the intermediate 
tertile have an (OR 2.2 (95% CI 1.2-3.9 p<0.001, p<0.001*). For ischemic stroke 
and for PAD this was not observed. 
Genetic variation of  ADAMTS13
The genotype distributions of  the ADAMTS13 SNPs were in Hardy- 
Weinberg equilibrium. None of  the SNPs was individually associated with levels of  
ADAMTS13 activity or antigen (Table 3). Haplotype analysis showed that 
haplotype GAAT was associated with lower levels of  ADAMTS13 activity (14% 
lower in the controls and 8% lower in the cases compared with the reference 
haplotype CGAT, p=0.05), but no association with ADAMTS13 antigen was 
observed. We did not observe a significant association between individual SNPs 
or haplotypes with the risk of  arterial thrombosis (Table 3). Haplotype GAAT 
was associated with a decreased risk of  PAD (OR 0.5, 95% CI 0.3-1.0, p= 0.06), 
There might be a reduced risk of  PAD in individuals with haplotype, but this 
estimate comes from a small group and needs to be considered with care and 
also needs replication in a larger cohort.
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Discussion
In this study, we show that levels of  ADAMTS13 are lower and levels of  VWF 
are higher in young patients with cardiovascular disease compared to healthy 
individuals. Individuals with low levels of  ADAMTS13 had five times more 
risk on cardiovascular disease than subjects with normal levels of  ADAMTS13. 
The relationship was strongest in the subgroup of  patients with coronary heart 
disease. This may be of  importance for identifying individuals who are prone to 
have a cardiovascular event.
We observed that high levels of  VWF are a risk factor for both myocardial 
infarction and stroke, which confirms previous studies.16-20  
Table 3 ADAMTS13 gene polymorphisms in cases and controls
Cases ADAMTS13 Controls ADAMTS13 OR(95% CI)
N= Act Ag N= Act Ag
RS2301612
GG 96 (28.7%) 94.9 77.9 97 (32.7%) 109.0 96.9 Reference
GC 174 (51.9%) 100.5 82.1 148 (49.8%) 110.5 98.1 1.21 (0.8-1.8)
CC 65 (19.4%) 90.7 78.7 52 (17.5%) 111.2 91.4 1.28 (0.8-2.1)
RS2073932
GG 107 (30.8%) 94.0 78.7 87 (28.8%) 111.4 97.8 Reference
GA 175 (50.4%) 99.4 82.1 156 (51.7%) 110.5 98.3 0.93 (0.6-1.3)
AA 65 (18.7%) 88.3 77.8 59 (19.5%) 102.5 94.1 0.85 (0.5-1.4)
RS652600
AA 167 (47.7%) 98.1 78.5 140 (46.8%) 112.0 97.8 Reference
AG 149 (42.6%) 98.5 82.8 134 (44.8%) 100.9 92.8 0.97 (0.7-1.4)
GG 34 (9.7%) 84.0 75.4 25 (8.4%) 107.2 98.2 1.10 (0.6-2.0)
RS603551
TT 302 (86.8%) 96.6 80.1 265 (85.5%) 110.9 97.6 Reference
TC+ CC 46 (13.2%) 98.7 87.1 45 (14.5%) 107.8 97.7 0.86 (0.5-1.4)
ADAMTS13 activity and antigen are in percentage of  Normal Pooled Plasma.
Logistic regression analysis with adjustment for age and sex.
Act = Activity, Ag = Antigen.
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The largest VWF multimers are the most thrombogenic and ADAMTS13 can 
cleave these ULVWF into smaller, less active forms, which suggests a role for 
ADAMTS13 in cardiovascular disease. Indeed, our study indeed showed that 
low levels of  ADAMTS13 are associated with a higher risk of  cardiovascular 
disease. In our study, we noticed that the relationship was stronger in coro-
nary heart disease than stroke, TIA and peripheral arterial diseases. These results 
are in accordance with two recent studies in elderly patients with myocardial 
infarction.11, 21 In our case-control study, we cannot prove a causal role for  the 
lower levels of  ADAMTS13. A prospective study could demonstrate whether 
ADAMTS13 is the cause or consequence of  the cardiovascular event. In 
contrast to our lower levels, one earlier study reported an increased risk of  AMI 
in men in the three highest quartiles of  ADAMTS13 antigen compared to the 
lowest quartile.10 The difference results may be explained by age and gender 
composition. Another difference between these studies and our study is the 
ADAMTS13 assay that is used. In our study we used an assay that measures 
both antigen and activity levels of  ADAMTS13 (Technoclone), and we observed 
similar associations with cardiovascular disease for ADAMTS13 activity and 
antigen. The other studies used an activity assay (FRETS assay)21 or an in-house 
ELISA based on monoclonal antibodies.21
We also showed that those individuals who have the lowest levels of  ADAMTS13 
combined with the highest levels of  VWF have the highest risk of  cardiovascu-
lar disease and that there is no correlation between ADAMTS13 and VWF levels 
(Rs= -0.12). An inverse correlation between ADAMTS13 and VWF was recently 
described in patients with Von Willebrand Disease.22
We observed an increased specific activity of  ADAMTS13 in patients 
compared with controls. The reduced ADAMTS13 activity levels are therefore not 
attributable to dysfunctional ADAMTS13. Despite the slightly higher specific 
activity levels of  ADAMTS13, both activity and antigen levels of  ADAMTS13 were 
lower in patients than in control individuals, thereby explaining the 
pro-thrombotic risk in these individuals. Feys et al. reported recently a lower specific 
activity of  ADAMTS13 in patients in pathologic conditions predisposing to 
thrombosis, but cardiovascular disease was not included in that study.23
A reduced activity of  ADAMTS13 in the Japanese population was seen in 
subjects with the 475Ser genotype with multimer degradation assays.24 How-
ever, the P475S polymorphism, associated with a striking reduction of  
ADAMTS13 activity, is not observed in Caucasians.6 We investigated whether 
other genetic variation in the ADAMTS13 gene is associated with ADAMTS13 
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levels, for which we studied four haplotype-tagging SNPs.  The SNPs separately 
were not associated with levels of  ADAMTS13. The lowest levels of  ADAMTS13 
were seen in haplotype GAAT Haplotype GAAT was associated with the risk 
of  PAD, however the number of  patients in this subgroup is small and larger 
studies are required to confirm this association. Since we did not observe 
associations between genetic variation and cardiovascular disease in the other 
groups, our study indicates that genetic variation in ADAMTS13 does not play 
a major role in the reduction of  ADAMTS13 levels found in our patients with 
cardiovascular disease. 
This study has some limitations. The controls that we included were healthy 
subjects without a history of  cardiovascular diseases. However, we did not screen 
for occult cardiovascular disease. Furthermore, for haplotype anaylsis, the group 
is somewhat small, but also single SNP analysis showed no strong associations. 
Significant associations need to be replicated and tested for clinical relevance 
in other, larger studies with independently collected cases and controls. Results 
from a case-control study do not prove causality and levels may be different 
because of  the event. However, since we collected samples one to three months 
after the event, the acute phase effect on the levels will be minimized. The 
ATTAC study consists mainly of  young, white Europeans and it is not clear 
whether the results of  our study can be extrapolated to other population.
In conclusion, we have shown that reduced levels of  ADAMTS13 are associated 
with an increased risk of  cardiovascular disease, but that genetic variation does 
not play a major role. 
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A Disintegrin and Metalloprotease with ThromboSpondin type 1 repeats 
(ADAMTS13) is a recently characterized metalloprotease that cleaves 
Ultra Large Von Willebrand Factor (ULVWF)1. A deficiency of  ADAMTS13 
results in an accumulation of  ULVWF, and leads to microangiopathic 
thrombosis, which is characteristic of  thrombotic thrombocytopenic purpura 
(TTP)2. The microangiopathic arterial thrombotic complications of  TTP occur 
predominantly in the brain. 
It is hypothesized that low ADAMTS13 levels may be a risk factor for arterial 
thrombosis, because less ULVWF cleavage may result in an excess of  high VWF 
multimers, resulting in more adhesion and aggregation of  platelets.3 
Recently, the proline (Pro) to serine (Ser) polymorphism in codon 475 of  the 
ADAMTS13 gene has been identified. This Pro475Ser polymorphism, caused 
by a base substitution of  C1423 to T in exon 12, is reported to impair the 
activity of  ADAMTS13. In a Japanese study the frequency of  the rare 475Ser 
allele of  this single nucleotide polymorphism (SNP) was 5.1% in 364 healthy 
controls and it has been suggested that the 475Ser allele may increase the risk of  
arterial thrombosis because of  the reduced activity of  ADAMTS13.3, 4
To study whether this ADAMTS13 polymorphism contributes to arterial 
thrombosis in Caucasians, we investigated the distribution of  the Pro475Ser 
polymorphism in a Caucasian population of  125 patients suffering from 
ischemic stroke and 125 age- and gender-matched healthy controls. 
The genotype was determined by polymerase chain reaction, digestion with RsaI 
and separation on a 2% agarose gel. We found that none of  the 250 individuals 
carried the rare 475Ser allele. 
We also investigated the Pro475Ser polymorphism in other populations, 
including 110 Chinese (HD02 and HD100 of  the Human Variation Panel, 
Coriell Institute for Medical Research, Camden, NJ, USA) where we found one 
heterozygous subject, giving a frequency for the 475Ser allele of  0.5% [95% 
confidence interval (CI) 0–2.9]. This confirms the results of  Ruan et al. who 
reported a frequency of  1.7% (95% CI 0.6–4.2) in healthy Chinese and 1.9% 
(95% CI 0.2–3.8) in Chinese patients who had had a myocardial infarction.5 Also 
in Afro-Americans (HD50), the 475Ser allele was not present.
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Since no 475Ser carrier for the polymorphism was identified in our study (95% 
CI 0–1.5%) we conclude that the Pro475Ser polymorphism, which is associated 
with a reduced ADAMTS-13 activity, is not an important contributor to the risk 
of  ischemic stroke in Caucasians. Our data suggest that outside the Japanese 
population, the 475Ser allele is very rare. 
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Introduction
In case of  a damaged blood vessel Von Willebrand Factor (VWF) binds to 
collagen in the subendothelium and mediates the adhesion of  platelets at the 
site of  vascular damage. Ultra Large VWF (ULVWF), secreted upon stimula-
tion, is degraded to a less active form by the metalloprotease ADAMTS13. The 
role of  VWF in arterial thrombosis has been studied intensively. In coronary 
heart disease high levels of  VWF are associated with an increased risk of  arte-
rial thrombosis.1, 2 We recently confirmed that elevated levels of  VWF antigen 
and activity are also a risk factor for ischemic stroke.3 Normally, the ULVWF 
multimers are cleaved by ADAMTS13 into smaller fragments that are less ac-
tive and less thrombogenic. It has been postulated that ADAMTS13 levels 
might also be associated with the risk of  arterial thrombosis.  In a recent study 
Ginsburg et al. showed that ADAMTS13 has a direct anti-thrombotic effect.4 
One of  the factors that determines the proteolysis of  VWF by ADAMTS13 
is the recently reported amino acid polymorphism Tyr1584Cys in exon 28 of  
the VWF gene, which encodes the A2 domain of  VWF. This polymorphism is 
associated with an increased susceptibility of  VWF for proteolysis by 
ADAMTS13.  Individuals who are homozygous for Tyr1584 have a normal 
proteolysis, while heterozygotes Tyr184Cys have an increased proteolysis. 
In Canadian patients with Von Willebrand Disease (VWD) type I the frequency 
of  this polymorphism was 14%, whereas in healthy Caucasian populations the 
estimate is around 1%.5-10 (Table 1).
An increased susceptibility to proteolysis of  VWF will lead to a decrease in less 
active circulating VWF molecules. The resulting anti-thrombotic effect could be 
a protective mechanism for arterial thrombotic disease. 
It has not yet been studied whether the Tyr1584Cys polymorphisms is associated 
with the risk of  arterial thrombosis. Therefore we investigated the Tyr1584Cys 
polymorphism in two different case-control studies in patients with well- 
documented arterial thrombosis.
Patients and Methods
Recently, we have performed two case-control studies on arterial thrombo-
sis. The first, the COCOS-study, has been described previously.11 Briefly, this 
study comprises 124 patients with a first-ever ischemic stroke and 125 controls 
without a history of  stroke with an age range between 18-75 years. The second 
study, the ATTAC-study, is a case-control study that comprises 374 young patients 
(males ≤ 45 years and females ≤ 55 years) with a first-ever arterial thrombotic
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Table 1 Allele frequencies of  the rare 1584C allele
Population N= Carriers Cys1584
(95%CI)
Reference
Type 1 VWD
Canadian
UK affected
MCMDM-1VWD index cases
MCMDM-1VWD index cases
unknown
76
104
153
14% 
25% 
7% 
8% 
5
7
8
9
Healthy control
Canadian healthy controls
MCMDM-1VWD controls
COCOS healthy controls
ATTAC healthy controls
200
1070
125
332
1% 
0.4% 
3.2% 
0.6%
5
8
This study
This study
Arterial thrombosis
COCOS (ischemic stroke patients) 124 0.8% This study
ATTAC (first arterial thrombosis) 374 0.5% This study
Vitamin K antagonist
FACTORS study
patients with bleeding
controls without bleeding
110
217
1.8% 
0 % 
10
10
event, including unstable angina pectoris, acute myocardial infarction, transient 
ischemic attack, ischemic stroke or peripheral arterial disease and 332 young 
population controls without a cardiovascular event. 
The Tyr1584Cys polymorphism in the VWF gene results from an 
A/G Single Nucleotide Polymorphism at 24/1584 (rs1800386). The relevant 
region of  exon 28 was amplified by PCR, using the forward primers: 5-‘AAGCCG-
GATTAGAACC-‘3 and reverse primer: 5’-AACTCCATGGTTGTGGAT-‘3. 
The primers contain 3 mismatches to avoid amplifying the VWF pseudogene. 
The PCR comprised 95°C for 4 minutes followed by 35 cycles of  94°C for 30 
sec, 65°C for 1 minutes, 72°C for 1 min and finally 72°C for 4 minutes. The 
PCR product (682bp) was digested with Kpn1, which cleaves the A-allele in two 
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fragments of  276 and 406, while the G-allele was not cleaved. The fragments 
were separated using 2% agarose gels and visualized using UV.
Results
In the COCOS study (mean age 56 years ± 12 (sd)) we observed similar 
carrier frequencies, 1 patient (0.8%) and 4 (3.2%) controls were heterozygote 
for Cys1584, p=0.48. No homozygotes for the 1584Cys allele were identified. 
In the ATTAC population (mean age 43± 7 (sd)) we observed no differences in 
carrier frequency between patients and controls (2 patients (0.5%) and 2 
controls (0.6%) who were heterozygotes, p=0.88. Also in this population no 
homozygotes were identified (Table 1.)
Discussion
Our study is the first to show that the Tyr1584Cys polymorphism has a similar 
low frequency for carriers of  the minor 1584Cys allele in patients with arterial 
thrombosis in two different study cohorts, and healthy controls.
The study cohorts included patients with coronary heart disease, ischemic stroke 
and peripheral arterial disease. Our findings are consistent with the frequencies 
in several healthy Caucasian populations.5,8 
Due to the limited size of  the study and the low frequency of  the 
Tyr1584Cys polymorphism we were not able to obtain a reliable estimate of  the 
contribution of  the polymorphism to the risk on arterial thrombosis.3 However, 
our data suggest that the Tyr1584Cys polymorphism has no protective effect on the 
occurrence of  arterial thrombosis. More and larger studies are required to assess 
the importance of  changes of  VWF proteolysis by ADAMTS13 as a potential 
pathogenic factor in arterial thrombosis.
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Abstract
Background
Multiple organ failure is a common feature of  pediatric meningococcal sepsis 
and is associated with an imbalance of  coagulation and fibrinolysis. This is partly 
due to an increased secretion of  prothrombotic Ultra Large Von Willebrand 
Factor (VWF) as the result of  vascular endothelial damage. Another factor that 
may contribute is ADAMTS13, which converts VWF into smaller, less active, 
VWF multimers and thus influences VWF activity in plasma. We investigated the 
role of  ADAMTS13 and VWF in the severity and outcome of  sepsis.
Methods
In 58 children with severe meningococcal sepsis we measured ADAMTS13 
activity and antigen, Von Willebrand Factor collagen binding activity (VWF:CB) 
and antigen levels (VWF:Ag), VWF propeptide and Factor VIII at different time 
points during their stay in the pediatric intensive care unit.
Results
In the acute phase, both ADAMTS13 activity and antigen were decreased 
(median 23.4% and 33.7% of  normal, respectively) and VWF:CB and VWF:Ag 
levels were strongly increased (325% and 348%, respectively.) ADAMTS13 
antigen (23.9% vs 34.6%; p=0.06) and VWF:CB (240% and 340% p<0.001) were 
lower in non-survivors than in survivors. ADAMTS13 activity and VWF:CB 
were both correlated with the severity of  the disease, as indicated by the 
Pediatric Risk of  Mortality score (rs= –0.38 and rs= -0.50, p=0.01 respectively, 
p<0.001).
Conclusion
In the acute phase of  severe sepsis decreased levels of  ADAMTS13 and 
increased levels of  VWF are observed, and the changes are related to severity 
of  disease and outcome. This may contribute to the formation of  microthrombi 
and the severity of  thrombotic sequelae of  sepsis. 
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Introduction
Meningococcal sepsis is characterized by a systemic inflammatory response to 
an infection with Neiseria meningitidis and is associated with multiple organ 
failure and an imbalance between coagulation and fibrinolysis. Although 
improved treatment possibilities have resulted in a decreased mortality, to date 
approximately 2% of  the meningococcal infections in developed countries are 
lethal.1, 2
In severe sepsis there is often excessive and sustained generalized 
activation of  the endothelium. Prolonged endothelial activation results in 
pro-inflammatory stimulation and a procoagulant state. Anticoagulants, such as 
antithrombin, activated protein C and Tissue Factor Pathway Inhibitor are 
depleted during sepsis and at the same time, fibrinolysis is inhibited, which 
further potentiates the formation of  microthrombi.3 A well-known marker of  
endothelial activation is Von Willebrand Factor (VWF). Upon endothelial cell 
stimulation or damage Ultra Large VWF (ULVWF) is actively secreted from 
the Weibel-Palade bodies in endothelial cells.4 VWF mediates platelet-platelet 
and platelet-subendothelial interactions and has therefore an important role in 
primary hemostasis. Furthermore VWF is also a carrier protein of  factor VIII. 
When ULVWF enters the circulation it is rapidly cleaved by ADAMTS13 at the 
1605-1606 bond in the A2 domain of  VWF into smaller, less active forms.
VWF levels are elevated in patients with arterial thrombosis such as acute 
myocardial infarction, stroke and peripheral vascular diseases.5-9 Also in sepsis 
elevated levels of  VWF have been reported indicating a possible contribution 
to microthrombi formation.10-11 Limited information is available on the role of  
ADAMTS13 in sepsis and only one small study (n=21) reported on decreased 
ADAMTS13 levels in children with sepsis.12-15 We hypothesized that reduced 
ADAMTS13 activity and increased VWF levels can contribute to the severity of  
the disease in children with severe meningococcal sepsis. We therefore studied 
the levels of  VWF and ADAMTS13 in children with severe sepsis in the acute 
phase and the convalescent phase of  the disease, in relation to inflammatory 
parameters, severity of  disease and outcome.
.  
Patients & Methods
Patients
Patients admitted to the pediatric intensive care unit (PICU) of  the Erasmus MC 
Sophia who previously participated in Rotterdam based meningococcal sepsis 
studies, were eligible for the current study.16, 17 These studies were approved by 
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the medical ethical committee. Children were enrolled after obtaining informed 
consent of  the parents or guardians. In 58 of  total of  71 patients, citrate blood 
was available.
Inclusion criteria were presentation with tachycardia, tachypnea, rectal 
temperature <36ºC or > 38.5ºC, and petechiae. Data on all patients were 
collected at various time-points in the course of  the disease (t=0, t=0.5 day, t=1 
day and t=90 days). The pediatric risk of  mortality (PRISM) score (based on blood 
pressure, heart rate, bilirubin, calcium, Pa O2, PaCo2, potassium, HCO3, 
glucose and Glasgow Coma Scale18, predicted death rate based on the 
Rotterdam score (based on serum potassium, base excess, platelet count and level of  
C-reactive protein)19, and the presence of  disseminated intravascular 
coagulation (DIC) were collected as markers of  severity of  disease on admission. 
DIC was defined as having a score of  5 or more on the DIC score, which included 
platelets, FDP or D-dimers levels, PT and fibrinogen.20 
Within 4 hours after admission to the PICU a baseline plasma sample was 
collected (t=0, n=58). Additionally blood was drawn at t=1 day, (n=50). 
Differences in number of  patients at different time-points are the result of  the 
fact that patients, with similar baseline characteristics, were included in several 
studies that did not all include a blood sample at t=0.5 day. Furthermore no 
samples were drawn when an arterial line was no longer available, when a patient 
was transported back to the referral hospital or when the patient died. Blood was 
drawn after 90 days to study the levels in the convalescent phase, but could only 
be obtained from 6 cooperative children. 
Some of  the children needed to be treated with coagulation factor concentrates, 
such as protein C. However, concentrates were given after the first blood draw, 
so all t=0 samples are without any influence of  coagulation factor concentrates. 
Until analysis the samples were stored at –80 degrees Celsius.
Plasma measurements
ADAMTS13 activity and antigen were measured using the Technozym 
ADAMTS13 kit (Technoclone, Vienna, Austria) as described by the manu-
facturer. Fluoresence was measured at 360/460 nm (Biotek reader FLX 800, 
Austria). The inter-assay variation was 10% for ADAMTS13 activity and 18% 
for ADAMTS13 antigen. Levels of  both ADAMTS13 antigen and activity in 
pooled plasma of  40 healthy men were defined as 100%
Von Willebrand Factor antigen (VWF:Ag) was determined with an in-house 
ELISA assay, using polyclonal rabbit anti-human VWF and horseradish 
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peroxidase conjugated anti-human VWF (DakoCytomation, Glostrop, 
Denmark) for catching and tagging, respectively. Von Willebrand Factor 
collagen binding (VWF:CB) activity was measured by an in-house ELISA 
using type I collagen (Sigma, St Louis, USA) for catching and horseradish 
peroxidase conjugated anti-human VWF. The inter-assay variations of  VWF:Ag 
and VWF:CB were 14.5% and 6.4% respectively.
VWF propeptide levels were determined by an ELISA using a polyclonal an-
tibody against recombinant VWF propeptide as capture and detection anti-
body, as described previously.21  Factor VIII was determined according to the 
one-stage clotting assay method on the Sysmex CA-1500 (Dade-Behring, 
Leusden, the Netherlands) with the APTT reagent Triniclot (Biomerieux, Boxtel, the 
Netherlands) and FVIII-deficient plasma (Biopool, Kordia, the Netherlands)
The concentrations of  C-reactive protein, Interleukin (IL-6), thrombin-anti-
thrombin complex (TAT) and plasminogen activator inhibitor I (PAI-I) were 
determined as described previously.22-24
Statistical analysis
Continuous parameters were not normally distributed. Therefore data were 
presented as median and analyzed using the Mann-Whitney U test. Binomial 
variables were analyzed using Pearson’s chi-square test or Fisher’s exact test 
when appropriate. Spearman correlation coefficient was determined to assess 
the correlation between ADAMTS13 levels and severity scores or other labora-
tory parameters. All ADAMTS13 levels were expressed as a percentage relative 
to normal pooled plasma. VWF levels were expressed in percentages of  normal 
pooled plasma. The statistical analysis was performed using SPSS version 11.0. 
P-values less than or equal to 0.05 were considered to be statistical significant.
 
Results
Patient characteristics
In total 71 patients with meningococcal sepsis were included in this study of  
whom from 58 patients citrated blood was available. The median age in this 
population was 5.5 years. The mortality rate was 12.6%. The baseline patient 
characteristics are presented in Table 1.
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Table 1 Patient characteristics in survivors and non-survivors
Total group
N=71)
Non-survivor
(N=9)
Survivor
(N=62)
P1-value
Male gender 44 (62%) 7 (78%) 37 (60%) 0.47
Age (min-max) 4.0 (0.1-16.1) 0.9 (0.5-9.4) 4.8 (0.1-16.1) 0.002
Presence of  shock 65 (93%) 9 (100%) 56 (92%) 1.0
Mechanical ventilation 45 (64%) 9 (100%) 36 (59%) 0.02
Presence of  DIC on 
admission
41 (58%) 9 (100%) 32 (52%) 0.008
DIC in first 24 hours 51 (72%) 9 (100%) 42 (68%) 0.05
PRISM score (first 6 
hours)
21 (4-43) 33 (23-43) 19 (4-37) 0.001
Predicted death rate 
based on Rotterdam 
score
9 (0-99) 94 (55-100) 6 (0-96) <0.0001
1 Fisher’s Exact test or Mann Whitney U test were performed when appropriate.
Data are presented as n (%) and median (min-max).
The median (min-max) ADAMTS13 activity (23.4% (8.3-49.4)) median (min-
max) and antigen levels (33.7% (13.2-83.9)) in the total group at admission were 
significantly decreased in children with sepsis compared to normal pooled plasma 
and levels increased at three months to 49.5% and 47.9%, respectively (p<0.001) 
(Figure 1). The specific activity of  ADAMTS13 (activity over antigen ratio) was 
0.7 (0.3-1.2) on admission and 1.2 (1.1-1.8) after three months (n.s). VWF CB 
(325% (149-637)) and VWF:Ag (348% (200-660) levels were strongly increased 
on admission and after t=12 and t=24 h and were (96% (54-120)) for VWF:CB 
and (76% (60-116))  for VWF:Ag at three months (Figure 1). The median (min-
max) level of  FVIII:C on admission was 67% (4-303). The ratio VWF:FVIII:C 
on admission was 4.6 (1.5-6.0) and 1.7 (1.4-8.0) after three months p=0.003. The 
ratio VWF:CB/ ADAMTS13 activity was calculated at all time points and was 9 
(4-27) at t=0 and normalized to 1 (1-5) at three months. The median (min-max) 
VWF propeptide levels upon admission were increased 27.8 to nM (8.0-47) and 
after three months 4.5 nM (2.9-6.5) p=0.14. 
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Plasma levels in survivors and non-survivors
On admission ADAMTS13 antigen was slightly higher (34.5% (14.5-83.8)) in 
survivors on admission, than in non-survivors (24.0% (13.2-41.8)) (p=0.06) 
(Table 2). ADAMTS13 activity in survivors was 24.3% (11.5-49.4) versus 
19.4% (8.3-27.6) in non-survivors. (p=0.19) In survivors the levels of  VWF:Ag 
were higher than in non-survivors (370% (240-660)) vs (240% (200-330)), 
p<0.001). Also the VWF:CB was higher in survivors than in non-survivors, 
(340% (160-640)) vs. (240% (150-320)), p<0.001) (Table 2). In survivors the 
levels of  FVIII:C (0.20 U/ml (0-0.6) were significantly lower than in non- 
survivors (0.8 U/ml (0-3.0)). The ratio VWF/FVIII:C on admission was 4.3 
(1.5-46.2) in survivors and 9.7 (3.4-60) in non-survivors, p=0.003. The ratio 
VWF:CB/ ADAMTS13 activity was higher in survivors than in non-survivors 
after 0.5 day. The propeptide levels were not significantly different in survivors 
compared to non-survivors (28.7 nM (8.0-47.0) versus 22.2 nM (21.9-34.6), 
respectively. At 90 days the VWF propeptide levels were normal in the survivors.
Figure 1 ADAMTS13 and VWF levels in the total study population.
Median ADAMTS13 and VWF levels (% relative to normal pooled plasma for ADAMTS13 and 
for VWF) on admission, after 0.5, 1 and 90 days are listed. The bars depict the ranges. 
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Table 2 ADAMTS13 and VWF levels in survivors and non-survivors
Day ADAMTS13 antigen P-
value
ADAMTS13 activity P-
value
Survivors Non-survivors Survivors Non-survivors
t=0 34.5 (14.5-83.8) 24.0 (13.2-41.8) 0.06 24.3 (11.5-49.4) 19.4 (8.3-27.6) 0.19
t=0,5 35.6 (29.5-67) 46.2 (45.8-46.6) 0.10 26.7 (15.5-54.9) 35.3 (27.7-43.1) 0.38
t=1 36.0 (19.7-66.2) 41.7 (25.7-57.9) 0.88 33.2 (13.9-65.3) 24.5 (20.1-28.9) 0.24
t=90 47.9 (6.0-57.2) 49.5 (16.8-70.9)
Day VWF antigen P-
value
VWF: CB P-
value
Survivors Non-survivors Survivors Non-survivors
t=0 370 (240-660) 240 (200-330) <10-3 340 (160-640) 240 (150-320) <10-3
t=0,5 310 (140-400) 240 (230-240) 0.21 280 (80-530) 130 (110-120) 0.06
t=1 320 (110-490) 210 (180-240) 0.04 300 (120-450) 120 (110-120) 0.02
t=90 80 (60-130) 100 (50-120)
Day Ratio VWF:CB/ADAMTS13 
activity
P-
value
Survivors Non-survivors
t=0 10 (5-27) 8 (4-19) 0.33
t=0,5 7 (1-15) 3 (2-3) 0.04
t=1 6 (2-16) 3 (3-4) 0.07
t=90 1 (1-5)
All values are presented in percentages of  normal pooled plasma
Plasma levels in patients with DIC and without DIC
For ADAMTS13 antigen no statistical difference between patients with 
DIC and without DIC was observed (Figure 2). However, ADAMTS13 
activity (min-max) on admission was lower in patients with DIC 19.4% 
(8.3-35.2) than in individuals without DIC 27.3% (11.5-49.4); (p=0.01). On 
admission VWF:Ag was higher in the patients without DIC (390% (250-590)) 
than in patients with DIC (330% (200-660)) p=0.03 (Figure 2). For VWF:CB 
there was no significant difference in levels at the various time points. FVIII:C 
levels on admission were significantly higher in patients without DIC 
(1.3 U/ml (0.5-3.0)) than in patients with DIC (0.4 U/ml (0.0-1.45) (p<0.001). 
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Figure 2 ADAMTS13 and VWF antigen levels in patients with and without DIC.
Median levels of  ADAMTS13 and VWF in patients with and without DIC are plotted. The 
closed squares represent the patients without DIC, the open squares represent the patients with 
DIC. The bar represents the range.
The ratio VWF/FVIII:C on admission was 2.7 (1.5-5.6) in patient without DIC 
and 8.3 (3.4-60) in patients with DIC, p=0.001. There was no difference in the 
ratio VWF:CB/ADAMTS13 activity in patients with DIC or without DIC. 
The VWF propeptide levels were similar in patients with DIC (28.5 (8.0-43.0) 
nM) compared to patients without DIC (26.5 nM (9.0-47.0)) p=0.57. 
Correlations with severity of  disease
All correlations were calculated at t=0. Both ADAMTS13 and VWF were nega-
tively correlated with the PRISM score and the predicted death rate based on 
the Rotterdam score (Table 3). There was no correlation between ADAMTS13 
antigen or activity and DIC parameters, such as thrombin-antithrombin (TAT) 
complexes and plasminogen activator inhibitor I (PAI-1). A positive significant 
correlation was seen for VWF with the levels of  CRP and age. Another inflam-
matory marker, IL-6, was negatively correlated with VWF activity (Table 3).
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Chapter 5
Discussion
In the present study, we showed that the plasma levels of  ADAMTS13 and VWF 
on admission were associated with the outcome of  meningococcal sepsis in 
children. Furthermore, a strong decrease of  ADAMTS13 and increase of  VWF 
were seen in the first 24 hours of  the disease and both correlated with disease 
severity. We observed a strong correlation between ADAMTS13 and markers 
for disease severity, such as the PRISM score, and the predicted death rate based 
on the Rotterdam score.
Since ADAMTS13 cleaves ultra large VWF multimers into smaller, less 
thrombogenic multimers, it is expected that low levels of  ADAMTS13 will 
result in more ULVWF in plasma and is therefore expected to result in a more 
thrombogenic state. Recently Bockmeyer et al. indeed showed that 
inflammation-induced ADAMTS13 deficiency is associated with the appearance of  
ULVWF in plasma.25 In sepsis patients in whom VWF levels are strongly 
increased this pro-thrombotic state may further worsen the outcome in these 
patients. 
In our study in a relatively large population of  children with meningococcal 
sepsis, we have shown a reduction in the levels of  ADAMTS13 activity and 
antigen in the acute phase of  the disease. These results are in 
concordance with previous studies in sepsis patients that reported that the levels of  
ADAMTS13 antigen and ADAMTS13 activity are decreased and levels of  VWF 
are increased.12-15 However, most of  these studies were in adult patients with 
sepsis-induced disseminated intravascular coagulation and it was not yet known 
whether the contribution of  ADAMTS13 to sepsis in children is similar to that 
in adults. Only one study had been performed so far in children which is in 
agreement with our study.15 In our study we showed for the first time that there 
is a relationship between ADAMTS13 and DIC and with outcome and sever-
ity of  the disease in children. In addition, lower levels of  ADAMTS13 were 
inversely related to outcome scores (Rotterdam score and PRISM score), 
which indicate that low ADAMTS13 levels are associated with poor prognosis. 
Levels of  ADAMTS13 antigen on admission were slightly lower (n.s) in the 
non-survivors than in survivors. ADAMTS13 was not correlated with age, but 
VWF was (Table 3). Age may play a role, since an immature state of  clotting 
system may cause a more severe coagulation state in young children.26
Interestingly, higher levels of  VWF were observed in the survivors com-
pared to the non-survivors. One explanation might be that this is caused by a 
decreased release of  VWF in the non-survivors, but it is expected that a more 
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severe disease results in increased endothelial damage and higher VWF lev-
els. An alternative hypothesis is that differences in VWF levels result from an 
increased consumption of  VWF in the non-survivors. To discriminate between 
these possible mechanisms, we measured the VWF propeptide, which is a 
marker for the secretion of  VWF. VWF propeptide was significantly increased 
in the first 24 hours and was normal after three months. No difference was seen 
between survivors and  non-survivors concerning the propeptide levels. This 
indicates that a decreased release of  VWF is not the cause of  the lower VWF 
levels in the non-survivors. The second mechanism, more consumption of  
VWF, is more likely since patients with DIC had significantly lower VWF 
levels than patients without DIC. This is further substantiated by the negative 
correlation between VWF with TAT, a marker of  coagulation activation. Also 
exhaustion of  storage pools could be an explanation for the differences in non-
survivor and survivor.
A limitation of  the study was that we compared the levels of  ADAMTS13 in 
septic children with the normal levels of  ADAMTS13 in adults. Nguyen et al. 
used as a control group children that were critically ill but did not have sepsis, 
and showed that in their control group of  children ADAMTS13 levels were 
around 85% of  adult reference values.15 Another limitation of  the study could 
be that we have not screened for ADAMTS13 inhibitors. This might influence 
the activity of  ADAMTS13. However, no influence on the antigen levels is 
expected.
Some patients with severe sepsis are treated with coagulation factor concentrates, 
such as protein C, which may improve the prognosis.27 However, patients were 
not treated with concentrates, such as protein C concentrate, before the first 
blood collection. Furthermore, we determined ADAMTS13 and VWF post-hoc. 
This can be seen as a limitation; however if  we had decided to measure these 
levels immediately, the study design would not have been changed and we would 
still have had the same end-point.
Our results show that ADAMTS13 is significantly correlated with the 
severity of  the disease. Infusion of  recombinant human-ADAMTS13 (r-hu-
ADAMTS13) has previously been shown to inhibit the thrombus growth and 
thereby the thrombus formation in ADAMTS13 deficient mice.28 It would be an 
interesting subject to investigate in future studies whether ADAMTS13 may 
be used to prevent thrombus formation. However, first, additional studies on 
ADAMTS13 levels in both children and adults with severe sepsis should be 
performed to confirm our findings before this approach is further explored.
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In conclusion, our study shows that levels of  ADAMTS13 are strongly reduced 
and levels of  VWF are strongly increased in children with meningococcal sepsis 
and that these levels are associated with severity and outcome of  the disease, 
likely by promoting the formation of  microthrombi in these affected children. 
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Abstract
Background
Cirrhosis of  the liver is frequently accompanied by complex alterations in the 
hemostatic system, resulting in a bleeding tendency. Although many hemostatic 
changes in liver disease promote bleeding, also compensatory mechanisms are 
found, including high levels of  the platelet adhesive protein von Willebrand 
Factor (VWF). However, conflicting reports on the functional properties of  
VWF in cirrhosis have appeared in literature. 
Methods
We have measured a panel of  VWF parameters in plasma from patients with 
cirrhosis of  varying severity and etiology. Furthermore, we assessed the contri-
bution of  VWF to platelet adhesion, by measuring the ability of  cirrhotic plasma 
to support adhesion of  normal platelets under flow conditions. 
Results
VWF antigen levels were strongly increased in patients with cirrhosis. In 
contrast, the relative collagen binding activity, as well as the relative ristocetin 
cofactor activity was significantly lower in patients as compared to controls, 
indicating loss of  function. Accordingly, patients had a reduced fraction of  high 
molecular weight VWF multimers. Both strongly elevated and reduced activity 
and antigen levels of  the VWF cleaving protease ADAMTS13 were found in 
individual patients. Adhesion of  either normal or patient platelets to a collagen 
surface was substantially increased when these platelets were resuspended in 
plasma of  patients with cirrhosis, as compared to control plasma. 
Conclusion
In conclusion, highly elevated levels of  VWF in patients with cirrhosis 
contribute to the induction of  primary hemostasis despite reduced functional 
properties of  the molecule. This phenomenon might compensate for defects in 
platelet number and function in patients with cirrhosis.
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Introduction
Cirrhosis of  the liver is often accompanied by extensive alterations in the 
hemostatic system. A decreased platelet count, impaired platelet function, 
a decreased thrombin generating capacity, defective fibrin formation due to 
dysfibrinogenemia, and defects in the fibrinolytic system may all be encountered 
in these patients (reviewed in 1). The net effect of  these hemostatic changes 
is a bleeding tendency, which may be particularly manifested during invasive 
procedures.
Although many of  the hemostatic changes found in patients with cirrhosis result 
in a reduced hemostatic capacity, compensatory mechanisms are also found. For 
example, the reduction in thrombin generating capacity caused by reduced levels 
of  procoagulant proteins is, in part, compensated by the concomitant reduction 
of  the natural anticoagulants.1 In fact, tissue factor-induced thrombin genera-
tion, which is substantially depressed in a prothrombin-like assay, is completely 
normalized on addition of  thrombomodulin which allows activation of  the 
anticoagulant protein C system.2 Similarly, the reduction in profibrinolytic 
proteins may (in part) be compensated by reduction of  antifibrinolytics.3, 4 
A mild to moderate thrombocytopenia and a poorly defined thrombocytopathia 
are often present in patients with cirrhosis, but its clinical relevance is unclear. 
A possible compensatory mechanism for these platelet abnormalities is the 
presence of  abnormally high plasma levels of  von Willebrand factor (VWF).5 
VWF is a large, multimeric protein with a crucial role in primary hemostasis, 
as evidenced by the severe bleeding tendency associated with complete VWF 
deficiency.6 Conversely, elevated levels of  VWF are associated with (arterial) 
thrombosis.7 Platelet-VWF interaction is the first step in platelet adhesion. After 
vessel wall damage, VWF from the circulation binds to exposed collagen fibers 
in the subendothelium. Once bound to collagen, VWF is able to interact with 
platelet glycoprotein Ib. Through transient VWF-glycoprotein Ib interactions, 
the platelet slows down, allowing subsequent stable interaction of  the platelet 
with collagen through the collagen receptors a2b1 and glycoprotein VI.
The elevated levels of  VWF in cirrhosis may be a consequence of  endothe-
lial perturbation, possibly caused by bacterial infection.5 Another possible 
mechanism of  elevated VWF in cirrhosis is induction of  synthesis of  VWF 
in the cirrhotic liver itself  8, or reduced liver-mediated clearance. Although it is 
established that VWF antigen levels are increased in patients with cirrhosis, 
relatively little is known on the functional capacity of  the protein in these 
patients. Conflicting reports on the capacity of  VWF to bind platelets (as 
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measured by ristocetin or botrocetin induced platelet aggregation) have 
appeared in literature, and patient numbers in these studies were small.5, 9, 10 An 
important qualitative aspect of  VWF is its multimeric composition. The high 
molecular weight multimers are more potent in supporting hemostasis, as they have 
a higher affinity for both glycoprotein Ib and collagen. The multimeric 
composition of  VWF is partly regulated by the VWF cleaving protease 
ADAMTS13. Reduced levels of  ADAMTS13 have been found in patients with liver 
disease, suggesting that elevated amounts of  high molecular weight multimers may 
circulate in these patients.11 However, the multimeric structure has been reported 
as either normal 5 or reduced 9, which may indicate that VWF proteolysis in liver 
disease is also accomplished by other proteases such as plasmin or elastase.12
In this study, qualitative and quantitative parameters of  VWF were measured 
in a large group of  patients with cirrhosis of  varying severity and etiology. 
Parameters examined were VWF antigen levels, VWF ristocetin cofactor activity, 
which is a measurement for the ability of  VWF to interact with platelet glyco-
protein Ib, the VWF collagen binding activity, the VWF cleaving protease AD-
AMTS13 antigen and activity, the multimeric structure of  VWF, and the levels 
of  the propeptide of  VWF. In addition, the ability of  cirrhotic plasma to support 
adhesion of  normal or patient platelets under flow conditions was examined. 
The combined results of  these assays provide more insight to what extent 
elevated VWF levels in these patients contribute to induction of  hemostasis.
 
Materials and Methods
Patients
Fifty-four patients with biopsy-proven cirrhosis of  various etiology – alcohol 
abuse 16, viral hepatitis 19, autoimmune hepatitis 2, primary biliary cirrhosis 4, 
cryptogenic cirrhosis 8, and others 5 – were included in this study. The patients 
were classified according to Pugh’s modification of  the Child classification.13 
Nineteen patients with Child A cirrhosis, 17 patients with Child B cirrhosis, 
and 18 patients with Child C cirrhosis were studied. In addition, 5 patients with 
acute liver failure were studied. Most patients were hospitalized for a short 
period as part of  a liver transplant screening program in a single institution 
(Erasmus MC, Rotterdam, The Netherlands) at the time of  inclusion. None of  the 
patients received transfusion of  platelet or plasma and did not use aspirin or other 
non-steroidal anti-inflammatory drugs in two weeks prior to the blood draw. 
One patient in the Child A and three in the Child C group were on antibiotics 
at the time of  the blood draw. One patient in the Child C group was admitted 
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to the hospital with sepsis and one was admitted for bacterial peritonitis. One 
patient in the Child C group had diabetes mellitus and hepatorenal syndrome.
A group of  40 healthy volunteers from our laboratory was used to establish 
reference values for all assays used. Pooled normal plasma was obtained by 
combining plasma from these healthy volunteers. In the platelet adhesion 
experiments pooled cirrhosis plasma was used. For this, plasma from 4 patients 
with Child’s A, 4 patients with Child’s B, and 4 patients with Child’s C (Pooled 
Child’s C) cirrhosis was combined. For the platelet adhesion experiments, we 
recruited 3 additional patients with cirrhosis (all 3 had Child’s C cirrhosis of  
alcoholic origin) and 3 healthy volunteers.
Blood samples were obtained by venipuncture from the antecubital vein into 
3.2% sodium citrate (9:1, v/v). To obtain platelet poor plasma, samples were 
centrifuged twice at 2000g for 15 minutes, after which the samples were stored 
at -70°C until use.
Assays
VWF antigen (VWF:Ag) levels were determined using the STA Liatest from 
Roche (Almere, The Netherlands) in the Behring Coagulation System (BCS, Dade 
Behring, Marburg, Germany). VWF ristocetin cofactor activity (VWF:RCo) was 
determined using the BC von Willebrand reagent (Dade Behring) on the BCS 
apparatus. VWF:Ag and VWF:RCo levels in pooled normal plasma were set at 
100%.
VWF collagen binding activity (VWF:CBA) was determined with an in-house 
assay. In short, collagen type III (Sigma, St. Louis, MO, USA) was dissolved in 
50 mM acetic acid, and dialyzed against phosphate-buffered saline to obtain 
fibrillar collagen. ELISA plates were coated with collagen (10 mg/well), blocked 
with PBS containing 3% bovine serum albumin and 0.1% tween-20. Plasma 
samples were diluted according to their VWF:Ag content. Two dilutions, 
corresponding to 5 and 2.5% of  the amount of  VWF present in pooled 
normal plasma were prepared and added to the wells. Bound VWF was visualized 
using a horseradish peroxidase(HRP)-conjugated polyclonal antibody against 
VWF (DAKO, Glostrup, Denmark). The collagen binding activity of  pooled 
normal plasma was set at 100%, and the values obtained in patient samples were 
expressed as % of  pooled normal plasma. 
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The VWF cleaving protease ADAMTS13 activity was measured using a rapid 
functional assay that determines the digestion of  VWF by ADAMTS13, based 
on the method described by Gerritsen.14 The activity of  ADAMTS13 in pooled 
normal plasma was arbitrarily defined as 1 U/ml. The values of  ADAMTS13 in 
tested plasma samples are read from a calibration curve achieved by incubating 
the VWF substrate with dilutions of  a normal plasma pool. The upper detection 
limit was 3 U/ml. 
ADAMTS13 antigen levels were measured by a commercially available 
ELISA according to the instructions of  the manufacturer (American Diagnostica, 
Stamford, CT).
VWF multimer analysis was performed by sodium dodecylsulphate agarose 
gelelectroforesis followed by western blotting according to Brosstad et al.15 The 
blots were scanned and analyzed by densitometric analysis (ImageQuant 5.2., 
Molecular Dynamics, Sunnyvale, CA). The first 5 bands were considered as low 
molecular weight multimers, whereas the other bands were designated as high 
molecular weight multimers.
VWF propeptide levels were determined by ELISA using a polyclonal antibody 
raised against recombinant VWF propeptide which was purified as described.16 
The catching and detecting antibody were the same, except that the detection 
antibody was conjugated with HRP. The propeptide level measured in pooled 
normal plasma was set at 100%.
Platelet adhesion experiments
The ability of  plasma from patients with cirrhosis to support platelet adhesion 
was studied under flow conditions in a reconstituted blood model. Red cells were 
isolated from whole blood from healthy volunteers who had blood group O as 
described previously.17 Platelets were isolated from 3 patients with cirrhosis and 
3 controls according to previously published methods.17 After the final washing 
step, platelets from patients or controls were resuspended in pooled normal 
plasma, or in pooled cirrhosis plasma. The platelets were mixed with red cells to 
obtain reconstituted blood with a platelet count of  200,000/ml and a hematocrit 
of  40%. In selected experiments, reconstituted blood with a reduced platelet 
count (25.000 or 100.000 platelets/μl) and a hematocrit of  40% was prepared. 
The reconstituted blood was perfused over a collagen type III-coated surface 
using a single-pass perfusion chamber(18) at a shear rate of  1600s-1. 
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Platelet adhesion under these conditions is completely dependent on VWF. 
After 2 minutes of  perfusion, the coverslips were stained with May-Grünwald and 
Giemsa as described previously.19 Platelet adhesion was evaluated using computer-
assisted analysis with OPTIMAS 6.0 software (Dutch Vision Systems [DVS], 
Breda, The Netherlands), and was expressed as the percentage of  the surface 
covered with platelets.    
Statistical analysis
Statistical analysis was performed using the GraphPad InStat software 
package (GraphPad, San Diego, USA). Differences in VWF parameters were 
examined by standard one-way analysis of  variance (ANOVA) using the Tukey 
post-test, except for differences in VWF propeptide, ADAMTS13 activity and 
antigen levels, and VWF multimer analysis which were assayed using the Kruskal 
Wallis ANOVA with Dunn’s post-test as in these measurements standard 
deviations were substantially different between groups, and values were not 
normally distributed. P values <0.05 were considered statistically significant.
Results
VWF:Ag levels substantially elevated in cirrhosis and acute liver failure
As shown in figure 1A, VWF:Ag levels were strongly elevated in plasma from 
patients with Child A (380% [165-980]; median [range]), Child B (500% [130-
1455]), and Child C (760% [385-1855]) cirrhosis compared to the reference 
group in which the median VWF:Ag level was 107% [38-180]) (P<0.001 for 
mild, moderate, and severe cirrhosis compared to control). In the 5 patients 
with acute liver failure, median VWF:Ag level was 790% [650-890] (p<0.01 
compared to control). When patients were classified according to the model for 
end-stage liver disease (MELD) score, we also observed a strong correlation 
between VWF:Ag levels and severity of  the disease as assessed by the MELD 
score. (r=0.448, p<0.001). For calculation of  the MELD score, we used the 
modified MELD score as employed by UNOS for organ allocation: MELD = 
[0.957 × loge (creatinine) + 0.378 × loge(bilirubin) + 1.12 × loge (international 
normalized ratio) + 0.64] × 10 (Available at: http://www.unos.org/resources). 
In accordance, mean MELD scores paralleled the Child classification. The 
MELD score was 10 [6-18] (median [range]) in the Child A group, 13 [7-23] in 
the Child B group, 18 [13-36] in the Child C group, and 28 [22-36] in the acute 
liver failure group.
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Figure 1 VWF:Ag levels (A), VWF:RCo levels (B), and VWF:RCo/VWF:Ag ratio (C) in pa-
tients with Child A, B and C cirrhosis and in patients with acute liver failure compared with VWF 
parameters as measured in healthy controls. VWF:Ag and VWF:RCo levels are expressed as a 
percentage of  pooled normal plasma. Horizontal lines represent medians. * p<0.001, ** p<0.01
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Substantially elevated VWF:RCo levels, but depressed VWF:RCo/
VWF:Ag ratio  in cirrhosis and acute liver failure
As shown in figure 1B, VWF:RCo levels were found substantially elevated in 
patients with Child A (300% [121-630]; median [range]), Child B (290% [40-
900]), and Child C (610% [240-1005]) cirrhosis compared to the reference 
group in which the median VWF:RCo level was 105% [33-222]) (P<0.001 for 
mild, moderate, and severe cirrhosis compared to control). In the 5 patients 
with acute liver failure, median VWF:RCo level was 505% [285-540] (p<0.001 
compared to control). However, the VWF:RCo levels are not elevated to the same 
extent as compared to the antigen levels. In other words, although the amount 
of  VWF is substantially elevated, it appears less functional with respect to glyco-
protein Ib binding. This is demonstrated by a significantly depressed VWF:RCo/
VWF:Ag ratio in all groups:  Child A (0.75 [0.48-1.064]; median [range]), Child 
B (0.60 [0.31-1.02]), and Child C (0.78 [0.41-0.93]) cirrhosis compared to the 
reference group in which the median ratio was 0.96 [0.67-1.538]) (P<0.001 for mild, 
moderate, and severe cirrhosis compared to control, see figure 1C). In the 
5 patients with acute liver failure, median VWF:RCo/VWF:Ag ratio was 0.61 
[0.38-0.70] (p<0.001 compared to control). The functionality of  VWF was 
reduced to the same extent in all patients as shown by a strong correlation 
between VWF:RCo and VWF:Ag levels (r=0.812 vs r=0.852 in the control 
group) (p<0.0001).
Reduced collagen binding capacity of  VWF in patients with cirrhosis and 
acute liver failure
As shown in figure 2, VWF collagen binding activity decreased with increasing 
severity of  the disease in patients with cirrhosis. VWF collagen binding activity 
was 95% [80-113] (median [range]) in Child A, 83% [42-98] in Child B, and 78 
[61-90] in Child C cirrhosis, while in the reference group in the median collagen 
binding activity was 98% [0.87-107] (P<0.001 for moderate and severe cirrhosis 
compared to control, p>0.05 for mild cirrhosis compared to control). In the 5 
patients with acute liver failure, the VWF collagen binding activity was slightly 
decreased (90% [86-99]), but this difference did not reach statistical significance.
96
Figure 2 VWF collagen binding capacity in patients with cirrhosis of  varying severity and in 
patients with acute liver failure as compared with the activity in plasma from healthy controls. 
The collagen binding capacity was measured at equal antigen levels of  VWF. The collagen bind-
ing capacity of  pooled normal plasma was set at 100%. Horizontal lines represent medians. 
* p<0.001
ADAMTS13 activity and antigen levels are highly variable in patients with 
liver disease
ADAMTS13 activity levels were determined using the collagen binding 
assay as described by Gerritsen.14 Compared to controls, ADAMTS13 levels in 
patients with cirrhosis showed a high variability, and both substantially elevated 
and substantially depressed ADAMTS13 levels were found in all patient groups 
as shown in figure 3A. Some patients had ADAMTS13 activity levels exceeding 
3 U/ml on repeated testing, even after a further predilution of  the sample prior 
to the assay. Mean ADAMTS13 levels in Child A and Child B cirrhosis were 
elevated compared to controls, but this difference did not reach statistical 
significance. As ADAMTS13 activity levels were previously reported to be 
decreased in patients with cirrhosis using the same assay used here 11, we decided 
to measure ADAMTS13 antigen levels as well. ADAMTS13 antigen levels also 
showed a high variability in the patient samples compared to the variation ob-
served in control samples as shown in figure 3B. ADAMTS13 antigen levels were 
significantly elevated in Child B (P<0.05) cirrhosis, and in patients with acute liver 
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failure (p<0.05) compared to controls, whereas the mean ADAMTS13 antigen 
levels found in Child A and Child C cirrhosis were not significantly different from 
the levels in the control group. The activity and antigen levels showed a weak, 
but statistically significant correlation (r=0.39, p=0.0029). Both ADAMTS13 
activity and antigen levels were negatively correlated with the VWF:RCo/
VWF:Ag ratio (r=0.29, p=0.29 for activity, r=0.61, p<0.0001 for antigen levels).
Figure 3 ADAMTS13 activity (A) and antigen (B) levels in patients with cirrhosis of  
varying severity and in patients with acute liver failure as compared with the levels measured 
in plasma from healthy controls. ADAMTS13 activity levels were calibrated to pooled normal 
plasma, in which the activity was set at 1 U/ml. ADAMTS13 antigen levels were calibrated using 
recombinant ADAMTS13 according to the instructions of  the manufacturer. Horizontal lines 
represent medians. * p<0.05, ns is not significant.
Reduced high molecular weight VWF multimers in plasma from patients 
with liver disease
We determined the multimeric pattern of  VWF in a subset of  the patients (12 
with Child A, 10 with Child B, 8 with Child C, and 3 with acute liver failure). 
Consistent with the collagen binding data, we observed a significantly decreased 
proportion of  high molecular weight multimers in patients with Child A (63% 
[32-74]; median [range]), Child B (66% [56-72]), and Child C (58% [52-77]) 
cirrhosis, compared to the amount of  high molecular weight multimers in the 
controls (73% [61-81]) (P<0.01 for mild and severe cirrhosis, and acute liver 
failure compared to control, p<0.05 for moderate cirrhosis compared to control) 
(figure 4). In the 5 patients with acute liver failure, also a decreased proportion 
of  high molecular weight multimers was observed (60% [33-61], p<0.01). The 
fraction of  high molecular weight multimers was negatively correlated with the 
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ADAMTS13 activity (r=-0.55, p<0.001), and with ADAMTS13 antigen levels, 
which almost reached statistical significance (r=-0.34, p=0.051). Also, a correla-
tion between the fraction of  high molecular weight multimers and VWF:RCo/
VWF:Ag ratio was observed (r=0.38, p=0.03).
Figure 4 The proportion of  high molecular weight (HMW) VWF multimers in patients with 
cirrhosis of  varying severity and in patients with acute liver failure as compared with the propor-
tion of  high molecular weight multimers in plasma from healthy controls. The proportion of  
high molecular weight multimers was estimated from densitometric analysis of  western blots of  
agarose gels. The first 5 visible bands were considered to represent the low molecular weight 
multimers. Horizontal lines represent medians. * p<0.01, ** P<0.05
Cirrhotic plasma supports VWF-dependent platelet adhesion better than 
normal plasma
The ability of  pooled cirrhosis plasma (VWF:Ag 402%, VWF:RCo 301%) 
cirrhosis to support adhesion of  normal platelets or platelets from patients 
with cirrhosis was compared to that of  pooled normal plasma (VWF:Ag 
and VWF:RCo 100%, per definition). The pooled plasma’s were added to 
isolated red cells and platelets from 3 healthy volunteers or 3 patients with 
cirrhosis and perfused over collagen type III for 2 minutes. As shown in figure 
5A, the amount of  platelets isolated from healthy controls or patients adhering 
to the surface was significantly higher when platelets were resuspended in pooled 
cirrhotic plasma as compared to resuspension of  the platelets in normal plasma. 
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Figure 5 Plasma from patients with cirrhosis better supports platelet adhesion than normal 
plasma. A) Pooled plasma from patients with cirrhosis or pooled normal plasma was mixed with 
red cells and platelets either isolated from healthy volunteers or from patients with cirrhosis and 
perfused over a collagen-coated coverslip for 2 minutes. After May-Grunwald staining, surface 
coverage was determined (shown are results from experiments with 3 different patients and 3 
different controls performed in triplicate, error bars indicate standard error of  mean). * P<0.01 
B) Morphological appearance of  the platelet thrombi on a collagen surface with reconstituted 
blood with patient or control plasma or platelets as indicated. Shown are representative examples 
of  the experiment presented in panel A. Original magnification is 400.
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Also, when normal or patient platelets were resuspended in pooled cirrhotic 
plasma, the aggregates were substantially larger as compared to the aggregate 
size obtained when platelets were resuspended in pooled normal plasma (figure 
5B). The adhesion of  platelets isolated from patients with cirrhosis was similar 
to that of  the adhesion of  platelets isolated from healthy controls under these 
conditions of  standardized platelet count and hematocrit. 
When normal platelets were resuspended in either normal or cirrhotic plasma 
under conditions representing thrombocytopenia (25.000 and 100.000 platelets/
ml, we also observed a significant elevation in platelet deposition when cirrhotic 
plasma was used (data not shown).
VWF propeptide levels 
As shown in figure 6, VWF propeptide levels were substantially elevated in Child 
A (488% [234-2942]; median [range]), Child B (711% [261-2190]), and Child C 
(735% [221-5129]) cirrhosis, while in the reference group in the median VWF 
propeptide level was 89% [30-237]) (P<0.001 for mild, moderate, and severe 
cirrhosis compared to control). Also in the patients with acute liver disease, 
elevated propeptide levels were found (1139% [803-1594], p<0.001).
Discussion
In this study, we have performed a comprehensive study on VWF in a large 
group of  patients with cirrhosis of  varying severity and etiology. Highly 
elevated levels of  VWF were found, which were strongly related to the severity 
of  the disease. However, the functional capacity of  the VWF decreased with 
increa-sing severity of  the disease as shown by a reduction in VWF:RCo/VWF:Ag 
ratio and reduced collagen binding capacity. Despite the suppressed binding 
capacity to both glycoprotein Ib and collagen, the highly elevated VWF 
levels in cirrhotic plasma resulted in a substantially elevated platelet deposition to 
collagen in a VWF-dependent, flow-driven platelet adhesion assay. This indicates 
that the quantitative increase in VWF in cirrhosis overrules the qualitative defects, 
and that the elevated levels of  VWF might in part compensate for the qualitative 
and quantitative platelet defects found in these patients. The increased adhesion 
induced by cirrhotic plasma was observed with both normal and patient 
platelets, and at normal and thrombocytopenic platelet counts.
Surprisingly, platelet deposition under conditions of  standardized platelet 
count and hematocrit were similar when normal or patient platelets were used, 
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Figure 6 VWF propeptide levels in patients with cirrhosis of  varying severity and in patients 
with acute liver failure as compared with the levels in healthy controls. The VWF propeptide 
level in pooled normal plasma was set at 100%. Horizontal lines represent medians. * p<0.001
suggesting that platelets in cirrhosis are functionally normal. This is in contrast
with experiments describing intrinsic platelet defects in cirrhosis (reviewed in 
1). However, the majority of  these experiments were performed under static 
conditions. 
The elevated VWF levels in cirrhosis possibly reflect endothelial damage, which 
has been suggested to be stimulated by endotoxemia (bacterial infection).5 
Another possibility is that the synthesis of  VWF is increased, since it was recent-
ly shown that liver disease induces VWF expression in the liver.8 Alternatively, 
VWF synthesis may be increased due to the substantially enhanced endothelial 
surface in patients with cirrhosis as a consequence of  extensive collateral forma-
tion. Also, the increased levels of  vasoconstrictors (notably vasopressin), which 
arise as a consequence of  the hyperdynamic state in these patients, could be 
responsible for elevated release of  VWF from the endothelium.20 Finally it may 
be possible that reduced VWF clearance contributes to elevated levels, but to 
our knowledge no experimental evidence has been presented so far. We have 
measured levels of  VWF propeptide in an attempt to investigate whether the 
elevated VWF levels represent acute endothelial damage, as found for example 
in patients with sepsis, or chronic endothelial perturbation such as found in 
patients with diabetes.21 As the half-life of  VWF propeptide is much shorter 
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compared to that of  VWF itself, only elevated levels of  VWF and normal to 
slightly elevated levels of  VWF propeptide are found in patients with chronic 
endothelial damage.21 The highly elevated propeptide levels found in patients 
with cirrhosis in our study suggest acute endothelial damage, which may be 
compatible with the presence of  (low-grade) disseminated intravascular 
coagulation (DIC) in these patients, although the presence of  DIC in cirrhosis 
has been debated.22 On the other hand, the increased propeptide levels may 
also be explained by a reduced clearance of  this molecule in patients with liver 
disease, or it may reflect persistent enhanced VWF synthesis by the diseased 
liver.8 The hypothesis that patients with cirrhosis have continuously enhanced 
VWF release into the bloodstream is supported by analysis of  the VWF 
propeptide/VWF:Ag ratio, which is slightly elevated in patients with Child’s 
A and B cirrhosis, but not different from controls in patients with Child’s C 
cirrhosis (data not shown). The VWF propeptide may have physiological 
relevance in the plasma environment in processes related to inflammation and cell 
adhesion (reviewed in 23). Whether the highly elevated VWF propeptide levels 
in patients with cirrhosis interfere with inflammatory or cell adhesion processes 
is unknown. It has also been shown that the propeptide may bind to collagen 
resulting in inhibition of  collagen-induced platelet aggregation24, 25, but our 
platelet adhesion studies do not support these observations. 
The clearly reduced VWF:RCo/VWF:Ag ratio, the reduced collagen binding 
activity, and the reduced proportion of  circulating high molecular weight 
multimers measured in this large group of  patients resolves the contro- 
versy of  VWF functional capacity in patients with liver disease. Previously, both 
increased and decreased functional VWF parameters were reported (reviewed 
in 1). From our study it has become clear that the functional capacity of  VWF is 
reduced in patients with cirrhosis. This may be caused by increased proteolysis by 
VWF proteases, such as plasmin or elastase.12 Recently a selective VWF cleaving 
protease has been discovered, which is important for cleavage of  large, active 
VWF multimers into smaller less functional multimers. Surprisingly we found a 
strong variability in ADAMTS13 levels in patients with cirrhosis.  These results 
are in contrast with a previous report in which significantly reduced levels were 
demonstrated in a group of  patients with Child’s C cirrhosis by Mannucci et 
al.11 In our patient group we find both elevated and reduced activity and antigen 
levels of  ADAMTS13. However, the measurement of  ADAMTS13 activity is 
difficult, and shows a large coefficient of  variation. A lot of  controversies on 
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ADAMTS13 activity measurement still exist, especially in cases with mild or 
moderately reduced levels.26 This is also illustrated by the relatively poor correla-
tion between the two assays used in this study. Moreover, although ADAMTS13 
levels would be expected to be decreased in cirrhosis, as it principle site of  
synthesis is presumably the liver27, it may also be that either reduced clearance, 
or release of  ADAMTS13 from platelets28 (as a result of  platelet activation 
secondary to DIC) lead to the elevated levels observed in some patients in our 
study. Alternatively, it might be possible that ADAMTS13 synthesis is induced 
in liver disease, as is has recently been shown that ADAMTS13 is synthesized 
in hepatic stellate cells29, which are known to show enhanced protein synthe-
sis in patients with liver cirrhosis30. Interestingly, ADAMTS13 antigen levels, 
and, to a lesser extent, ADAMTS13 activity levels were negatively correlated 
with VWF:RCo/VWF:Ag ratio, indicating that the excess of  ADAMTS13 in 
some patients results in excessive VWF proteolysis, resulting in impaired VWF 
activity. This is also supported by the negative correlation observed 
between ADAMTS13 levels and the proportion of  high molecular weight VWF 
multimers. These data also suggest that in those patients with high levels of  
ADAMTS13, the reduced functional capacity of  VWF is a direct consequence 
of  excessive ADAMTS13 proteolysis.
In conclusion, highly elevated levels of  VWF in patients with cirrhosis 
contribute to the induction of  primary hemostasis despite reduced functional 
properties of  the VWF molecule. This phenomenon might compensate for 
defects in platelet number and function, which are present in patients with 
cirrhosis. 
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Abstract
Background
ADAMTS13 degrades ultralarge highly active von Willebrand Factor into 
smaller, less active multimers. Extreme Low levels of  ADAMTS13 are 
associated with thrombotic thrombocytopenic purpura (TTP). Recent studies 
have indicated that more subtle reduced levels of  ADAMTS13 are associated 
with microthrombi and arterial thrombosis. Therefore it is of  utmost importance 
to precisely measure ADAMTS13 activity and antigen levels of  ADAMTS13 in 
these conditions.
Several assays have recently been developed. It is however unclear how to 
interpret the results of  these assays in different patients groups. 
Methods
In this pilot study we compared three activity assays (Gerritsen assay, FRETS, 
Technozyme activity) and two antigen assays (Technozym antigen and ELISA 
American Diagnostica) in plasma samples from healthy individuals (n=60), 
patients with thrombotic thrombocytopenic purpura (TTP, n=41) and patients 
with liver cirrhosis of  different severity (n=50). 
Results
All activity assays measured very low levels in patients with TTP (levels < 20 %). 
As expected in patients with acquired TTP, higher levels of  ADAMTS13 antigen 
levels were measured compared to ADAMTS13 activity. In healthy controls, the 
five assays measured slightly different levels. For all assays the range of  the levels 
measured in cirrhosis patients was very wide and the correlation between the 
various assays was weak. This could not be explained by bilirubin levels or other 
patient characteristics and further research is needed to explain these findings.
Conclusion
In conclusion, ADAMTS13 activity assays are all able to identify patients with 
TTP, but their performance in patients with liver cirrhosis is unclear.
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Introduction
Patients with thrombotic thrombocytopenic purpura (TTP) suffer from 
intravascular platelet aggregation and microthrombi, what can result in ischemia 
and arterial thrombosis.1 If  untreated, TTP is a life-threatening disease and 
therefore it is of  utmost importance to rapidly and accurately diagnose this 
disease. Platelet aggregation and formation of  microthrombi are caused by 
unusually large Von Willebrand Factor multimers (ULVWF). These ULVWF 
are the result of  the absence of  the protease ADAMTS13 (A Disintegrin And 
Metalloprotease with ThromboSpondin type-1 motifs 13), which is responsible 
for the cleavage of  VWF into smaller, less active, VWF molecules. ADAMTS13 
thus regulates the size of  VWF multimers and prevents the formation of  
spontaneous platelet aggregates by ULVWF. 
The deficiency of  ADAMTS13 in TTP patients can be genetic or acquired, 
and in the latter situation it is caused by antibodies that inhibit the activity 
of  the protease. An inhibitor to ADAMTS13 strongly reduces ADAMTS13 
activity but may be associated with normal ADAMTS13 antigen levels. Therefore a 
discrepancy can be found between the measurement of  protein concentration 
of  ADAMTS13 and its activity. 
ADAMTS13 is primary synthesized in the liver by stellate cells, and we 
previously showed that ADAMTS13 levels are decreased in patients with liver 
cirrhosis.2, 3 Surprisingly, we observed a very large variability of  ADAMTS13 
levels and VWF levels in patients with liver cirrhosis.3 Both very high (>300%) 
and very low (<30%) ADAMTS13 levels were observed in liver cirrhosis 
patients, independent of  their severity of  the cirrhosis.3 The cause for this 
variability is not explained so far.
In recent years a number of  assays have been introduced for the 
measurement of  ADAMTS13. These assays are based on different test principles. 
The first assay developed for the measurement of  the activity of  ADAMTS13 was 
described by Gerritsen et al.4 In this assay, purified VWF is incubated with 
the patient sample and the decrease of  VWF collagen binding activity is an 
indirect measurement of  the ADAMTS13 activity.  Recently, a number of  other 
assays for the measurement of  ADAMTS13 levels and activity have been intro-
duced. The FRETS-VWF73 assay is an activity assay that uses a fluorescence- 
labeled peptide, containing the cleavage site of  ADAMTS13.5 Also the 
ADAMTS13 Technozym assay measures ADAMTS13 activity.6 In this test 
ADAMTS13 is first added to a microtiter plate coated with anti-ADAMTS13 
antibodies, and then in a second step, the activity of  the bound ADAMTS13 is 
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determined by measuring the change in fluorescence. This assay also allows the 
determination of  ADAMTS13 antigen via incubation with a tagging monoclonal 
antibody to ADAMTS13. Another ELISA using specific monoclonal anti-
bodies against ADAMTS13 for measurement of  ADAMTS13 antigen levels is 
commercially available (American Diagnostica, Stamford, CT). 
Each of  these assays has its potential advantages and disadvantages. An 
important difference between the assays is the type of  substrate that is used. The 
Gerritsen assay uses purified VWF as a substrate and theoretically measures all 
VWF-cleaving-proteases. The FRETS assay and the Technozym ADAMTS13 
assay are more specific for ADAMTS13, but use a synthetic peptide as substrate, 
which is different from the natural substrate VWF. In the FRETS assay, high 
bilirubin levels may interfere with the FRETS-VWF73 substrate.7 Although 
the Technozym assay uses the same substrate, this problem is not to be 
expected, since bilirubin is washed away. A disadvantage of  the Gerritsen assay 
is that it is labour-intensive, time-consuming and has a high assay variability. In 
contrast, the FRETS assay is fast and reproducible.
The aim of  our study was to compare the above mentioned assays available 
for measuring ADAMTS13 in healthy individuals, in patients with TTP and in 
patients with liver cirrhosis.
 
Patients and Methods
Patients
Forty-one patients with TTP were included in the study. These patients were 
included on admission to the Erasmus MC Rotterdam, the Netherlands in the 
acute phase of  the TTP, before the start of  treatment. Patients were diagnosed 
with TTP when patients had thrombocytopenia, microangiopathic hemolysis 
and clinical symptoms of  TTP. Sixty healthy individuals were included in the 
study as a reference.
In addition, fifty patients with biopsy-proven cirrhosis of  the liver were 
included. These patients were diagnosed at the Erasmus MC. The patients were 
classified according to Pugh’s modification of  the Child classification.8 Nineteen 
patients had Child A cirrhosis, 16 patients Child B cirrhosis, and 15 patients 
Child C cirrhosis. The etiology varied from alcohol abuse, viral hepatitis, 
autoimmune hepatitis, primary biliary cirrhosis to cryptogenic cirrhosis.
Blood sampling
Blood samples were obtained by vena puncture from the antecubital vein into 
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3.2% sodium citrate (9:1, v/v). Samples were centrifuged twice at 2000g for 15 
minutes, after which the plasma was stored at -70°C until use.
Gerritsen ADAMTS13 activity assay 
ADAMTS13 activity according to Gerritsen et al, was performed according to 
literature, with some minor modifications.4, 9 Briefly, plasma is incubated for 
two hours with purified VWF as substrate for the protease. The supernatant 
was then added to a microtiter plate that has been coated with collagen. After 
incubation, the VWF bound to collagen is measured using a peroxidase-labled 
anti-human VWF polyclonal antibody and compared to normal pooled plasma. 
The intra-assay variation was 11 %.
ADAMTS13 FRET-VWF73 assay
ADAMTS13 activity was measured as previously described by Kokame.5 Briefly, 
samples were diluted with assay buffer and FRETS-VWF73 substrate (Thermo 
elektron GmbH, Ulm, Germany; Peptide institute Inc, Osaka, Japan) was added 
to each well. Fluorescence was measured every 5 minutes at 30ºC in a multi-
label counter (Biotek reader FLX 800, Austria) at 340 nm excitation and 450 nm 
emission. The reaction slope was calculated by linear regression analysis and 
the ADAMTS13 activity was then calculated by comparing the slope to that of  
normal pooled plasma (George King). The intra-assay variation was 6 %. 
ADAMTS13 assay (activity and antigen)
ADAMTS13 activity and antigen were measured using the Technozym 
ADAMTS13 activity and antigen fluorogenic ELISA kit (Technoclone, Vienna, 
Austria), performed as described by the manufacturer. Briefly, diluted plasma 
samples were incubated on micro-titer plates coated with a monoclonal antibody 
against ADAMTS13. After two hours incubation the plates were washed and 
an activity substrate was added. The fluorescence was measured for 15 minutes 
(1 measurement per minute) at 30ºC and ADAMTS13 activity was calculated. 
The plate was then washed and incubated with a monoclonal antibody against 
ADAMTS13. A fluorescent labeled antigen substrate was added and after an 
incubation of  15 min at 37ºC the reaction was stopped and the fluorescence 
was measured at 340 nm excitation and 450 nm emission (Biotek reader FLX 
800, Austria) and ADAMTS13 antigen was calculated. All levels are expressed 
as percentage of  normal pooled plasma (%PP)(George King). The intra-assay 
variation was 6 % for ADAMTS13 activity and 6% for ADAMTS13 antigen. 
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ADAMTS13 antigen
The ADAMTS13 antigen levels were determined by a commercially 
available ELISA and were performed as described by the manufacturer (America 
Diagnostica, Stamford, CT). The assay gives levels in ng/ml, which we expressed 
in percentage of  pooled plasma. 
 
Results
TTP patients
In the TTP patients, the Gerritsen assay, the FRETS assay and the Technozym 
assay identified the patients with very low ADAMTS13 levels (Table 1). In the 
Gerritsen assay, levels were 4 ± 3 % (mean±SD), with the FRETS assay it was 
1 ± 3 %, with the Technozym activity assay 3 ± 2 %, with the Technozym 
antigen assay 34 ± 42 % and with the American Diagnostica ADAMTS13 
ELISA 25 ± 31% (156 ± 111 ng/mL). The Spearman rank correlation between the 
ADAMTS13 activity assays (rs between 0.47 and 0.85) and the antigen assays 
(rs between 0.43 and 0.93) was good, but weak between activity and antigen 
assays (Table 2). 
Table 1 ADAMTS13 activity and antigen in healthy controls and patients with TTP
Healthy controls (N=60) Patients with TTP (N=41)
ADAMTS13 activity assays
Gerritsen assay (%PP) 91 ± 15 4 ± 3
FRETS assay (%PP) 111 ± 42 1 ± 1
Technozym activity (%PP) 136 ± 42 3 ± 2
ADAMTS13 antigen assays
Technozym antigen (%PP) 135 ± 33 26 ± 41
ELISA (%PP) 127 ± 39 25 ± 31
Levels are presented as mean ± SD
Healthy individuals
In the 60 healthy individuals, the levels of  ADAMTS13, measured with the 
different assays, showed a clear variability (Table 1). In the Gerritsen assay, levels 
were 91 ± 15 % (mean±SD), with the FRETS assay it was 111 ± 42 %, with the 
Technozym activity assay 136 ± 42 %.  ADAMTS13 antigen levels measured 
with the Technozym antigen assay were 135 ± 33 % and with the American 
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Diagnostica ADAMTS13 ELISA 126 ± 39% (698 ± 214 ng/mL). The correla-
tion between the assays in the healthy controls was good between the FRETS 
assay and the Technozym activity and antigen assays, but was weak between the 
other tests (Table 2).
Table 2 Spearman Rank Correlation between the various ADAMTS13 assays in healthy con-
trols, patients with TTP and patients with liver cirrhosis.
 Gerritsen FRETS Technozym:act Technozym:Ag
Total group
Gerritsen
FRETS 0.79*
Technozym:act 0.28* 0.57*
Technozym:Ag -0.28* 0.38* 0.87*
AD:Ag 0.79* 0.74* 0.27* -0.13
Healthy controls
Gerritsen
FRETS n.d.
Technozym:act -0.38 0.76*
Technozym:Ag 0.37 0.62* 0.76*
AD:Ag -0.16 n.d. -0.24 0.42
TTP
Gerritsen
FRETS 0.69
Technozym:act 0.47 0.85*
Technozym:Ag -0.29 n.d. 0.61
AD:Ag 0.14 0.30 0.43 0.93*
Liver
Gerritsen
FRETS 0.57*
Technozym:act -0.52* -0.35*
Technozym:Ag -0.58* -0.28 0.80*
AD:Ag 0.54* 0.69* -0.42* -0.38*
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Liver cirrhosis patients
In patients with cirrhosis, the range of  ADAMTS13 activity and antigen levels 
varied from very low to very high with all assays (Table 3). 
In the Gerritsen assay levels of  ADAMTS13 were remarkably high 165% 
(43-361) (median (10th-90th percentile)) in Child A, while this was 45% (14-96) 
for Technozym activity assay and 50 % (24-112) for the FRETS assay. In Child 
B the median levels of  ADAMTS13 activity with the Gerritsen assay were 136% 
(43-361), 34% (29-135) for the Technozym activity assay and 51% (4-152) for 
the FRETS assay.  In Child C we found 75% (34-274) in the Gerritsen assay, 
59% (17-84) for the Technozym activity assay and 43% (10-118) for the FRETS 
assay. 
The levels of  ADAMTS13 antigen in Child A were 26% (6-78) with the 
Technozym antigen assay and 137% (59-364) with the ELISA.
In Child B the levels of  ADAMTS13 antigen were 41% (14-185) with the 
Technozym antigen assay and 172% (62-364) with the ELISA. In Child C the 
levels of  ADAMTS13 antigen were 66% (18-138) with the Technozym assay and 
121% (55-306) with the ELISA.
The correlation between the different activity and antigen assays is variable and 
weaker than in the healthy controls and the TTP patients (Table 2). Adjustment 
for bilirubin levels or excluding individuals with high bilirubin levels did not 
influence our results.
 
Table 3 ADAMTS13 in patients with liver cirrhosis
Child A (N=19) Child B (N=16) Child C (N=15)
Activity
Gerritsen 165 (43-361) 136 (43-361) 75 (34-274)
Technozym activity 45 (14-96) 34 (29-135) 59 (17-84)
FRETS 50 (24-112) 51 (4-152) 43 (10-118)
Antigen
Technozym antigen 26 (6-78) 41 (14-185) 66 (18-138)
ELISA 137 (59-364) 172 (62-364) 121 (55-306)
Levels are given as median (10th-90th percentile).
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Discussion
In this paper we have shown that currently commercially available ADAMTS13 
assays are able to correctly identify patients with TTP. Furthermore, most 
assays for ADAMTS13 activity and antigen showed a good correlation in healthy 
individuals and TTP patients. We also show that in patients with various degrees 
of  severity of  liver cirrhosis, the ADAMTS13 levels in the various assays show a 
wide variability ranging from very low to high levels.
For the diagnosis of  TTP, it is very important that patients with low ADAMTS13 
activity can be accurately identified. In our study, all available ADAMTS13 
assays were able to identify patients with TTP. This is in agreement with the recent 
collaborative study on ADAMTS13 methods by Tripodi and colleagues.10  All our 
patients had acquired TTP and therefore have inhibitors against ADAMTS13 
(data not shown), which explains the discrepancy between activity and antigen 
as has been reported previously. 
In the healthy individuals, the levels of  ADAMTS13 varied quite a lot. This was 
observed for all assays, independent of  the analytical variation. Also, in patients 
with liver cirrhosis, a wide range in levels was seen for the various tests. When 
we first observed this wide range in our previous study on ADAMTS13 levels 
in patients with liver cirrhosis, using the Gerritsen assay, we proposed that the 
large analytical variation of  the Gerritsen assay might be a contributing factor to 
the observed wide range.3 The current study shows however, that a wide range 
is also seen with other assays, and also to some extent in healthy individuals. It 
is known that high levels of  bilirubin can disturb the FRETS assay, but this did 
not explain our observations with the other assays.7
In addition, the correlation between the ADAMTS13 levels measured with the 
different tests both in healthy individuals and patients with liver cirrhosis were 
weak. It is remarkable that results of  some assays are negatively correlated. 
These data indicate that it is yet unclear which test can be used best to study 
ADAMTS13 levels in liver cirrhosis patients. Our results are in contrast with 
those in a recent study by Uemura and colleagues11 who observed a good 
correlation in 142 liver disease patients between ADAMTS13 levels measured by 
act-ELISA (Kainos Inc), VWFM assay (Gerritsen assay) and ADAMTS13 
antigen (home made ELISA). It was remarkable that the range of  ADAMTS13 
levels in this study was smaller than in our patient group. However, only the 
Gerritsen assay was used both in the Japanese study and in our study, which 
makes it difficult to really compare the results.
We conclude that the current assays are all able to identify patients with TTP. 
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However, in other study populations than TTP, such as patients with liver 
disease, the measurement of  ADAMTS13 is probably depending on other 
factors and the optimal test to measure ADAMTS13 in population has to be 
determined. Also for other disease state associated with alterations in 
ADAMTS13 levels studies using different ADAMTS13 assays should be 
performed. 
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The aim of  this thesis was to determine the role of  ADAMTS13 in the 
pathogenesis of  cardiovascular disease and to study its potential role in 
2 other pathological conditions predisposing to thrombosis. We hypothesized that 
reduced levels of  ADAMTS13 will result in higher levels of  VWF and more 
high molecular weight VWF multimers. These high levels of  VWF might 
contribute to a higher risk of  arterial thrombosis. To test this hypothesis we 
measured ADAMTS13 levels in several patient cohorts with cardiovascular 
disease in chapter 2 and 3. We studied the relationship between ADAMTS13 
levels and variations in both VWF and ADAMTS13 gene, in chapter 4a and 
4b. Furthermore ADAMTS13 was studied in other pathological conditions, 
associated with coagulation disturbances and a prothrombotic state, including 
liver cirrhosis and meningococcal sepsis, in chapter 5 and 6. 
ADAMTS13 levels in cardiovascular disease 
VWF is released into the circulation constitutively and after damage of  the 
endothelium. VWF is released as ultralarge VWF multimers, which form 
high-strength bonds with the platelet glycoprotein Ib-IX-V complex, resulting 
in platelet aggregation and thrombus formation. The process of  endothelial 
damage and thereby the release of  VWF into the circulation may be a pathoge-
netic mechanism in patients with ischemic stroke or myocardial infarction.  
In two case-control studies we observed that levels of  VWF were strongly 
elevated in patients with arterial thrombosis compared to healthy controls. 
Individuals with VWF levels in the highest quartile had a 2-fold increased 
risk of  arterial thrombosis.1, 2 This might indicate that increased VWF may 
result in an increased risk of  cardiovascular disease. However, since patients were 
included after the event occurred, these high levels may be a consequence rather 
than a cause of  the ischemic event. Other groups have also studied VWF levels 
to assess whether VWF is a risk factor for cardiovascular diseases in previously 
healthy individuals.3 A meta-analysis of  five prospective studies indicated that 
VWF is a weak independent risk factor for future cardiovascular disease OR 1.2 
(95% CI 0.8-1.9).4, 5 However, in persons with pre-existing cardiovascular disease 
this association is even stronger, also after adjustment for cardiovascular risk 
factors, in particular in myocardial infarction patients. A meta-analysis of  eight 
prospective studies in pre-existing vascular disease revealed a combined odds 
ratio of  1.6  (95% CI 1.0-2.5).6 
ADAMTS13 is a metalloprotease that cleaves VWF into smaller multimers, 
which leads to less active VWF. The role of  ADAMTS13 in cardiovascular 
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disease is yet unknown. In the studies described in this thesis we found that 
the levels of  ADAMTS13 were significantly lower in patients with arterial 
thrombosis than in healthy controls.1, 2 These findings were most significant in 
the study of  young individuals with cardiovascular disease under the age of  45 
years for men and under 55 for women. The risk of  arterial thrombosis was 
five-fold higher for individuals in the lowest quartile versus the highest quartile 
of  ADAMTS13 levels OR 5.1 (95% CI 3.1-8.5).2 Only a few other studies have 
investigated ADAMTS13 levels in patients with cardiovascular disease. The 
results from these studies show conflicting results. Two small studies 
determined ADAMTS13 levels in acute myocardial infarction patients shortly 
after the event, directly on admission or 14 days after the event.7, 8 They reported 
reduced levels of  ADAMTS13 and increased levels of  VWF in the acute phase. 
ADAMTS13 and the ratio of  VWF/ADAMTS13 were significant predictors for 
in-hospital cardiovascular events after acute myocardial infarction. However, the 
SMILE study reported an increased risk of  myocardial infarction in individuals 
with higher levels of  ADAMTS13.9 This is a remarkable finding since all other 
studies so far reported reduced levels of  ADAMTS13 in cardiovascular disease. 
In this study only men were investigated with an age-range from 18-70 years. 
Also the moment of  blood sampling was different from the other studies. Blood 
sampling occurred at least 6 months after the event, with a median of  2.6 years 
after the event, while other studies measured in the acute phase or at the latest 6 
months after the event.
Our subgroup analysis in the ATTAC population indicates that the associa-
tion of  ADAMTS13 with the risk of  arterial thrombosis was strongest in the 
coronary heart disease group. Individuals in the lowest tertile of  ADAMTS13 
had a eight-fold higher risk of  AMI versus individuals in the highest tertile OR 
8.2 (95% CI 4.5-14.7). The risk of  ischemic stroke patients was slightly higher 
for individuals with lower level of  ADAMTS13 but was not statistical significant 
in both the COCOS study OR 1.7 (95% CI 0.7-3.9) and ATTAC study OR 1.8 
(95% CI 0.9-3.1). An explanation for this finding could be a lack of  statistical 
power due to the relative small number of  ischemic stroke patients. Another 
possibility is the complexity of  stroke etiology compared to that of  myocardial 
infarction. Only one experimental study reported about the role of  ADAMTS13 
in stroke. Zhao et al. showed that in mice with ADAMTS13 deficiency in whom 
an experimental stroke was induced, the infarct size was increased and that mice 
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with reduced or absent VWF had smaller infarct sizes. In addition, infusion of  
ADAMTS13 in ADAMTS13 knock-out mice reduced the infarct volume and 
functional outcome, without producing cerebral hemorrhages.10 
Genetic variation in ADAMTS13 and VWF in cardiovascular 
disease
It has been hypothesized that genetic predisposition to arterial thrombosis may 
be associated with variations in a single gene. Within a gene, a single nucle-
otide polymorphism (SNP) or a combination of  SNPs that inherit together 
(haplotype) can be studied. In our studies we used a haplotype approach to 
comprehensively cover the total common variation in the ADAMTS13 gene. 
By using tools from the HAPMAP consortium and SeattleSNPs database we 
selected four haplotype tagging SNPs. We studied the possible association of  
the individual SNPs and the haplotypes with the risk of  arterial thrombosis. 
For none of  the SNPs or haplotypes an association was found. The SNPs and 
haplotypes did no show any correlation with the levels of  ADAMTS13.  This 
indicates that other factors may be more important in influencing the levels 
of  ADAMTS13 than genetic variation in the ADAMTS13 gene. Recently, two 
other studies have been published that have investigated genetic variations 
in ADAMTS13. The first study, the MASS II study, reported that the minor 
allele of  the genetic variant A900V in patients with coronary artery disease was 
associated with an increased risk of  death OR 1.9 (95% CI 1.1-3.2) and death 
from cardiac cause OR 2.7 (95% CI 1.6-4.5).11 The second study, the SAHLSIS 
study, investigated 6 SNPs of  the ADAMTS13 gene in patients with ischemic 
stroke.12 Three minor alleles of  these SNPs showed an association with ischemic 
stroke. One minor allele of  these SNPs (rs4962153) showed an increase in risk 
OR 1.25 (95% CI 1.01–1.54), while the other two minor alleles of  rs2285489 
and rs2301612 had a decreased risk of  ischemic stroke; OR 0.82 (95% CI 0.70–
0.97) and OR 0.85 (95% CI 0.73–1.00) respectively.12 Hanson et al. studied two 
of  the four SNPs that we assessed in the ATTAC study. The assay for one of  
these SNPs (rs2073933) was non-functional and could not be replaced. Another 
SNP (rs 2301612) was associated with a decreased risk of  ischemic stroke. The 
number of  patients in the study by Hanson et al was higher than in our  ATTAC 
study (n=600 versus 109 ischemic stroke patients). In our study the power may 
have not been sufficient to find an association between the ADAMTS13 SNPs 
and the risk of  arterial thrombosis. Another difference between the studies was 
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that our study population was a more heterogeneous group of  patients, since 
we included not only ischemic stroke patients, but also patients with myocardial 
infarction and peripheral arterial disease. Another difference was the age dis-
tribution of  the two studies. Whereas we looked at young patients with CVD, 
Hanson et al. studied patients with an age of  70 or younger. The selection of  the 
SNPs differed in the various studies because less SNPs were known based on the 
available databases (HAPMAP and Seattle SNP) at the time that our study was 
performed. Furthermore, we have selected on the bases of  allele frequency of  
the SNP (> 0.05) and have selected SNPs where possible on the functionality of  
the SNP. In both of  our case-control studies mainly Caucasians were included.
It is known that in Japanese the minor allele of  the ADAMTS13 polymorphism 
P475S is present in approximately 10% of  the population.13 The minor allele of  
this polymorphism is associated with reduced activity of  ADAMTS13. It was 
hypothesized that this polymorphism may increase the risk of  arterial throm-
bosis because of  the reduced activity of  ADAMTS13. We therefore studied this 
polymorphism in patients with cardiovascular disease to assess the association 
between this polymorphism and cardiovascular disease. The minor allele of  this 
polymorphism was however absent in both cases and controls of  our Cauca-
sian study population. We investigated P475S also in a group of  Chinese and 
Afro-Americans. In this study the minor allele was very rare in Chinese or 
absent in Afro-Americans, respectively. We therefore concluded that the P475S 
polymorphism is not an important player in the development of  arterial 
thrombosis in Caucasians.
 
The levels of  VWF are influenced both by acquired (environmental) and 
genetic factors. From twin studies it is known that approximately two-third of  all 
variation in levels of  plasma VWF is genetically determined, of  which 25-30% 
can be explained by ABO blood group.14 Individuals with blood group O have 
lower levels of  VWF compared to individuals with blood group non-O. We 
confirmed this in our study. Subgroup analysis in individuals with blood group 
O compared with individuals with blood group non-O showed that an increased 
risk was seen for the levels of  VWF antigen. One possible explanation could 
be the difference in clearance of  VWF due to the difference in glycosylation. 
Another possible explanation could be that there is linkage disequilibrium 
between ABO blood group and ADAMTS13. The location for ABO blood 
group is located on chr9q34, which also encodes for ADAMTS13. The locus for 
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ABO blood group is indeed found to be in linkage disequilibrium with the locus 
for ADAMTS13. 
An increased frequency of  the minor allele of  the Tyr 1584Cys polymorphism 
in the VWF gene has been reported in patients with Von Willebrand disease.15 
A large study showed increased proteolysis of  VWF in heterozygotes.16 We 
hypothesized that this polymorphism could be protective in patients with 
arterial thrombosis due to increased proteolysis of  VWF. We could not estimate 
the contribution of  the polymorphism to the risk of  arterial thrombosis because 
of  the low frequency and the limited number of  patients. Therefore, our data 
suggest that the minor allele of  the Tyr1584Cys polymorphism does not have 
a strong protective effect for arterial thrombosis. More and larger studies are 
required to assess the importance of  changes of  VWF proteolysis by 
ADAMTS13 as a potential pathogenic factor in arterial thrombosis.
Methodological issues
To investigate the role of  ADAMTS13 and VWF in cardiovascular diseases we 
initiated two case-control studies. An advantage of  a case-control study is that it 
provides a rapid inclusion of  individuals in the study. In addition we were able to 
collect precise data on diagnosis, treatment and prognosis. However, this study 
design has also some disadvantages and methodological considerations that 
needs to be discussed.  In a case-control study the levels of  ADAMTS13 and 
VWF are determined after the occurrence of  the event, making a definite causal 
inference impossible. The impact of  an ischemic event might stimulate patients 
to change their life style and to live a healthier life. For example, patients may 
change their exercise pattern, smoking behaviour, which in turn may affect the 
levels of  ADAMTS13 and VWF. In addition, patients will be treated with statins 
and other drugs that may affect VWF levels. Increased levels of  VWF are found 
in hypertensive individuals and therefore the levels could also be influenced by 
the use of  antihypertensives.17 The effect of  these drugs on ADAMTS13 has 
to be established in future studies. A prospective study does not have these 
above-mentioned limitations. In our studies however, we were able to adjust for 
the use of  statins and antihypertensives. 
The first study (COCOS) has included 124 patients with ischemic stroke, 
while the second case-control study (ATTAC) included, besides stroke patients 
(n=109) also patients who suffered from an acute myocardial infarction (n=218) 
or peripheral arterial disease (n=47). Although the total number of  stroke 
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patients in both studies is similar, the study populations differ in age. The 
average age in the COCOS study was 56 years. The ATTAC study was initiated to 
study the role of  coagulation factors in arterial thrombotic disease in the young, 
and the average age was 43 years.  It has been reported that age influences the 
levels of  ADAMTS13.18 ADAMTS13 activity and antigen were lower in healthy 
individuals of  65 years and above. Feys et al. studied ADAMTS13 levels in both 
physiological conditions and pathological conditions with prothrombotic state. 
They divided their patients in various age groups (<35 yrs, 36-50, 51-65, >65 
yrs). The levels of  ADAMTS13 were not significantly different in the first three 
age groups. Only individuals that were above 65 years had significantly lower 
levels of  ADAMTS13 activity. Since patients included in our study were 
all younger than 65 years, we expect no influence of  age on the levels of  
ADAMTS13 activity. An effect of  sex on the levels of  ADAMTS13 has been 
described.19 Therefore, we adjusted for sex in both studies, which had only a 
minor effect on the levels and the risk of  arterial thrombosis. 
Another consideration is that we cannot exclude that our population is a 
selection of  the total group stroke or myocardial infarction patients, since we 
only included patients that survived the event. We therefore cannot exclude that 
the studied polymorphisms in our study are associated with a fatal thrombotic 
event. Also this issue should be investigated in a prospective study.    
The levels of  VWF and ADAMTS13 can be influenced by several 
methodological factors. The first factor of  influence is the time of  sampling 
after the event. In the COCOS study blood was collected at 7-14 days after 
the event. Within this time frame an effect of  the acute phase may still be 
present, which is known to increase VWF levels.20 In the ATTAC study, the lag 
time between the event and the recruitment was one to three months, which 
ensures that transient inflammatory changes due to the event have disappeared. To 
further exclude the effect of  acute phase in the COCOS study, we corrected for 
CRP in our analysis.  This only had a minor effect on the risk estimate of  arterial 
thrombosis in the COCOS study.
It has been hypothesized that even though the levels of  ADAMTS13 are not 
severely decreased in plasma, the levels could be different between the systemic 
circulation and locally for instance at the site of  vascular injury. This implies that 
the site of  blood sampling may be of  importance. Horii et al investigated in a 
study of  coronary heart disease patients the levels of  ADAMTS13 and VWF in 
samples from the femoral vein, aortic root and coronary sinus.21 They showed 
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in the acute phase shortly after the cardiac event that at all sampling sites, VWF 
was higher than in the controls. ADAMTS13 was similar at all sampling sites. 
After six months additional samples were taken at three sites and there was no 
difference anymore in levels of  VWF between cases and controls. This study 
implies that the hypothesis of  locally reduced levels of  ADAMTS13 is unlikely, 
and that our study design with peripheral blood sampling is adequate.
Some coagulation factors are known to have a circadian effect. Also for 
ADAMTS13 this has been investigated.21 It appeared to be a minimal effect 
during the day. We included the majority of  our population in the morning and 
only few of  them in the early afternoon. Therefore we think that this is of  minor 
or no influence on the levels of  ADAMTS13 in our study population.
ADAMTS13 in other pathological conditions
The liver plays a pivotal role in hemostasis since it synthesizes clotting factors, 
coagulation inhibitors and fibrinolytic proteins. Also ADAMTS13 is synthesized 
in the liver in hepatic stellate cells.22 In a healthy individual there is a balance 
between prothrombotic and antithrombotic factors. However, in patients 
with liver cirrhosis many alterations are seen. A bleeding tendency may be the 
result of  reduced synthesis of  clotting factors and thrombocytopenia, but on the 
other hand patients with liver disease also exhibit thrombotic complications.23 
Thus it may be the result of  a changed balance in both primary and secondary 
hemostasis. It is well known that ULVWF is released due to endothelial activa-
tion. The role of  ADAMTS13 levels in the hemostatic balance in liver cirrhosis 
is not yet completely understood.18, 24, 25 Some individuals with liver cirrhosis have 
circulatory levels of  endotoxins that may alter VWF and ADAMTS13 
levels.26 We hypothesized that reduced synthesis of  ADAMTS13 results in low 
ADAMTS13 levels and thereby more active VWF in circulation. We found in 
some patients very low levels of  ADAMTS13 whereas others had high levels 
of  ADAMTS13. This variation was not caused by the severity of  the cirrhosis, 
but was found in Child A, B and C. Our results are in part in accordance with 
previous studies.23, 27 Most studies have found decreased levels of  ADAMTS13 
in all patients with liver cirrhosis. The type of  assay that was used in the 
various studies could explain part of  the variation. Therefore we used four 
different assays, including the Gerritsen assay28, an commercially available 
ELISA (American Diagnostica,Stamford, CT) a commercially available fluoro-
genic assay (Technozym, Vienna, Austria) and the FRETS assay19 and compared 
these findings in chapter 6. High levels of  VWF:Ag, that are often found in 
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patients with liver cirrhosis, may influence the ADAMTS13 assay by 
Gerritsen et al.   Hyperbilirubin has been reported to influence the FRETS assay of  
ADAMTS13 activity.29 However, in our study we did not find an association 
between bilirubin and the levels of  ADAMTS13 in the various group of  
patients with liver cirrhosis. Another possibility for the differences could be the 
aetiology of  liver cirrhosis of  the patients. Our study has included a limited 
number of  patients to perform subgroup analysis. This should therefore be 
evaluated in larger studies. 
Meningococcal sepsis and disseminated intravascular coagulation (DIC) are 
associated with a prothrombotic and systemic inflammatory state. Cytokines 
may influence the activity of  ADAMTS13. The role of  inflammation on the 
levels of  ADAMTS13 is not clear yet, but some studies have reported reduced 
ADAMTS13 activity in patients with acute inflammation or sepsis.30-32 In sepsis 
elevated levels of  VWF have been reported indicating a possible contribution 
of  VWF to the formation of  microthrombi. Therefore we studied the role of  
VWF and ADAMTS13 in a large group of  children with meningococcal sepsis. 
We showed that the levels of  ADAMTS13 were strongly reduced and VWF 
levels were elevated at admission and that they were associated with the out-
come of  meningococcal sepsis in children. Martin et al found that ADAMTS13 
was negatively associated with the APACHE score.33 Furthermore they showed 
an association between ADAMTS13 levels and hemodynamic shock, renal 
failure and survival.33 Other studies reported no association between ADAMTS13 
and the severity of  disease or outcome.34, 35. A recent study suggested a role of  
ADAMTS13 deficiency in the development of  sepsis-associated thrombocyto-
penia and organ failure. This makes that ADAMTS13 can be seen as a possible 
link between inflammation, endothelial dysfunction and coagulation.36
However, one should be careful to use the levels of  ADAMTS13 already as a 
diagnostic tool, since the levels show a wide range in a normal healthy 
population. Therefore there may be overlap can be seen between 
pathological conditions and healthy controls. Furthermore, it is not clear yet, 
what is threshold level of  ADAMTS13 activity for a true functional deficiency. 
Further research is needed to investigate ADAMTS13 in a model under flow 
conditions to see whether ADAMTS13 is consumed in conditions of  high 
shear stress with ULVWF and to study whether the activity of  ADAMTS13 is 
insufficient under these conditions.
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Assays 
To determine the ADAMTS13 antigen levels and activity of  ADAMTS13 
several commercial assays nowadays are available. These assays have their 
advantages and disadvantages. All assays were initially designed to diagnose a 
severe ADAMTS13 deficiency, as seen in TTP patients. However, it is not yet 
investigated in other patient groups how these assays perform. Therefore we 
studied the levels of  ADAMTS13 activity and antigen in TTP patients, healthy 
controls and patients with liver cirrhosis using various assays.
We showed that all assays were able to correctly diagnose TTP patients, by 
measuring a very low ADAMTS13 activity. However, for the other group that 
we measured, including patients with liver cirrhosis, these assays performed 
differently and the correlation between the various assays was poor. Therefore 
we conclude that it is not clear yet which assay should be used in patients with 
liver cirrhosis. First, more studies should be performed using these various 
assays to study the levels of  ADAMTS13, before the best available assay for 
certain populations can be indicated. Additional studies are necessary to unravel 
which factors influence the different assays.
Future perspective
To further investigate the role of  ADAMTS13 in arterial thrombosis, a study 
design with a prospective inclusion is required. With baseline values and several 
time-points before and after the event, the role of  ADAMTS13 in time should 
be studied. For the determination of  ADAMTS13 the most ‘ideal’ assay should 
be used.What is this ‘ideal’ assay? First of  all, the coefficient of  variation should 
be low. The Gerritsen assay for example still has a large coefficient of  variation 
and is not suited for these prospective studies. An ideal assay should not be 
time-consuming or require special equipment. 
Recently it has been demonstrated that there is a correlation between cholesterol 
and ADAMTS13.37 The highest association was observed for HDL-cholesterol 
that correlated negatively with ADAMTS13 (beta-coefficient = -0.68).  For total 
cholesterol a positive correlation was observed (beta-coefficient = 0.205). This 
is a remarkable finding given the fact that high cholesterol levels are a strong 
risk factor for arterial thrombosis.  Therefore, in future studies the lipid profile 
should be assessed in addition to ADAMTS13 levels. 
Elastases and cytokines are reported to inhibit ADAMTS13 activity.31, 38 It 
would be helpful in future studies to take also these factors into account. This 
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information could contribute to further unravel the relation between 
inflammation and thrombosis. 
Finally, it would be helpful to study more comprehensively the function of  VWF 
and ADAMTS13, by determining ULVWF besides VWF antigen and activity 
levels by multimer analysis. Using this method the precise amount of  very active 
VWF can be determined. 
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Summary
The main objective of  this thesis was to investigate the role of  ADAMTS13 
in arterial thrombosis. Arterial thrombosis, as seen in myocardial infarction 
and ischemic stroke, is an important cause of  death in the Western world. 
Many factors are already known to be a risk factor for cardiovascular diseases. 
However, other factors are still waiting to be discovered. These other 
factors both comprise environmental factors and genetic factors. Both of  these 
will be studied in this thesis. Chapter 1 is a general introduction of  this thesis. 
Background information about VWF and ADAMTS13, pathogenesis of  arterial 
thrombosis is reviewed to provide an overview of  the current knowledge of  
ADAMTS13 and VWF.  
In Chapter 2 we determined whether ADAMTS13 also plays a role in arte-
rial thrombosis. We studied a population of  124 patients with ischemic stroke 
or transient ischemic attacks and 125 healthy controls, the COCOS study. 
We studied the relationship between the levels of  ADAMTS13, VWF and 
ischemic stroke as well as a polymorphism in VWF gene in order to identify 
important risk factors for ischemic stroke. In the COCOS study the levels of  VWF 
were significantly higher compared with the controls. Elevated levels of  VWF 
antigen and VWF activity were also associated with a higher risk of  ischemic 
stroke OR 3.2 (95% CI 1.4-7.5) and OR 2.1 (95% CI 0.9-4.8), respectively (Q1 
vs Q4). Inflammation (C-reactive protein), ADAMTS13 and genetic variation in 
the VWF gene did not affect the association between VWF and the odds ratios 
for ischemic stroke. 
Secondly, a larger case-control study, ATTAC study, Chapter 3, was performed 
to study more comprehensively the relationship between ADAMTS13 levels, 
polymorphisms in the ADAMTS13 gene and the risk of  arterial thrombosis. 
This study comprises 374 young patients with a first myocardial infarction, 
ischemic stroke or peripheral arterial diseases and 332 healthy young controls. 
The inclusion criteria for age was 45 years or younger for men and 55 years or 
younger for women. The levels of  ADAMTS13 were associated with the risk 
of  arterial thrombosis OR 5.1 (95% CI, 3.1-8.5) (Q4 vs Q1). Also the levels 
of  VWF were associated with the risk of  arterial thrombosis OR 2.1 (95% CI, 
1.3-3.3) (Q1 vs Q4). However, the four SNPs did not show a clear relation-
ship with the levels or the risk, levels of  ADAMTS13 appeared to be strongly 
associated with arterial thrombosis. 
In chapter 4, we investigated the role of  two polymorphisms in the ADAMTS13 
and VWF gene. The first polymorphism, Pro475Ser, in the ADAMTS13 gene 
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causes a substitution of  C1423 into T in exon 12. This polymorphism is known 
to influence the activity of  ADAMTS13. We studied P475S polymorphism in 
the COCOS study. In our Caucasian population the rare allele was absent. We 
conclude that the P475S polymorphism is not an important contributor 
to the risk of  ischemic stroke in Caucasians. Furthermore we studied this 
polymorphism in a panel of  Chinese and Afro-American subjects. The 
frequency for the 475S allele was 0.5% in Chinese and 0% in Afro-Americans. 
Therefore, our data suggest that except for Japanese the rare allele is very rare.
The second polymorphism studied, is the Tyr1584Cys polymorphism, 
which is located in VWF gene, exon 28. This polymorphism is in literature 
associated with an increased proteolysis of  VWF. Increased proteolysis of  VWF 
causes detoriation of  ultralarge VWF multimers and prevents thereby that VWF 
remain large and can spontaneously form platelet aggregates and a thrombus. 
We were interested to study this polymorphism in relation to arterial thrombo-
sis. This polymorphism was studied in two different case-control studies with 
well-documented arterial thrombosis (COCOS and ATTAC). The frequency of  
the rare allele was 0.5-0.8% in the cases and 0.6-3.2% in the controls. Since 
the frequency of  the Tyr1584Cys polymorphism was low we were not able to 
obtain a precise estimate of  the contribution of  the polymorphism to the risk on 
arterial thrombosis. However, we conclude from our data that the Tyr1584Cys 
polymorphism does not play an important role in the risk of  arterial thrombosis.
The aim of  chapter 5 was to study the role of  ADAMTS13 in other 
pathological condition than cardiovascular diseases. Patients with sepsis 
often suffer from thrombotic complication. Therefore we studied in chapter 
5 the levels of  ADAMTS13 in pediatric patients with meningococcal sepsis. 
During severe meningococcal sepsis both ADAMTS13 antigen and activity are 
severely reduced compared to normal (23.4% and 33.7% of  normal, respec-
tively). Also lower levels of  ADAMTS13 (rs=-0.38) and elevated levels of  VWF 
(rs=-0.50) were associated with a severe outcome, indicated by the Pediatric Risk of  
Mortality Score (PRISM). Our study clearly demonstrates that in the acute phase 
of  severe sepsis the levels of  ADAMTS13 are reduced and that the levels of  
VWF are elevated. Furthermore, these data show that these changes are related 
to the severity of  the disease.
Chapter 6 concerns the role of  ADAMTS13 and VWF in patients with liver 
cirrhosis. Cirrhosis of  the liver is often accompanied by extensive 
alterations in the haemostatic system. Most changes result in reduced haemostatic 
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capacity, but also compensatory mechanisms have been found, for 
example abnormal high levels of  VWF. The cleavage of  VWF mainly occurs by 
ADAMTS13, which is primarily synthesized in the liver. Therefore, the aim of  
this study was to study the relationship of  VWF and ADAMTS13 in patients 
with liver cirrhosis. VWF antigen levels were significantly higher in patients 
with liver cirrhosis compared with controls (Child A 380%, Child B 500% and 
Child C 760% versus 107% in controls). The antigen levels of  VWF were also 
strongly correlated with the severity of  the disease (assessed by the model for 
end-stage liver disease (MELD)). VWF:RCo activity levels were also elevated in 
patients with liver cirrhosis, but not in the same extent as compared with the 
antigen levels. This means that the amount of  VWF is substantially elevated, but 
appears less functional with respect to the glycoprotein Ib binding. Levels 
of  ADAMTS13 activity in all patients showed a high variability as well as the 
antigen levels of  ADAMTS13 (varying from 0.19-3.0 U/ml). The multimeric 
pattern of  VWF in patients with liver cirrhosis was decreased compared to 
controls. The proportion high-molecular-weight multimers were in Child A 63%, 
Child B 66% and Child C 58% compared with the controls 73%. The propep-
tide levels of  VWF were increased in all patients with liver cirrhosis (Child A 
488%, Child b 711% Child C 735% compared to controls 89%). We concluded 
that the highly elevated levels of  VWF contribute to the induction of  prima-
ry hemostasis. Furthermore, we expected to find a decrease in ADAMTS13 in 
cirrhosis, since ADAMTS13 is primarily synthesized in the liver. However, we 
find in some patients reduced levels of  ADAMTS13, but in others elevated 
levels of  ADAMTS13. Therefore, we concluded that it is not completely 
clear yet, whether ADAMTS13 is reduced in liver cirrhosis or not. Reduced 
clearance or release of  ADAMTS13 from platelets may lead to elevated levels of  
ADAMTS13. Further studies are needed to investigate this on a larger scale.
In Chapter 7 several assays for measuring ADAMTS13 activity and/ or antigen 
are described. A large variety has been observed between the several assays. We 
compared the levels of  ADAMTS13 antigen en activity in patients with TTP and 
liver cirrhosis. We concluded that for the identification of  TTP patients all assays 
are suitable. However, there no clear answer yet which assay should be used in 
patients with liver cirrhosis or what caused the large variability in liver cirrhosis 
patients.
In Chapter 8, our findings are discussed and reviewed in a broader context. 
Overall, we can conclude that the levels of  ADAMTS13 play an impor-
tant role in arterial thrombosis with an increased risk on arterial thrombosis, 
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especially in patients with coronary heart disease. This was confirmed in several 
independent case-control studies. Of  course, all results were derived from 
case-control studies and need to be further studied in prospective studies. 
Furthermore chapter 8 describes more suggestions for further research.  
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De belangrijkste doelstelling van dit proefschrift was om de rol van 
ADAMTS13 in arteriële trombose te onderzoeken. Arteriële trombose (zoals 
een hartinfarct of  herseninfarct) is de belangrijkste oorzaak van sterfte in de 
Westerse wereld. Door onderzoek zijn er al vele risicofactoren geidentificeerd bij 
hart- en vaatziekten. Echter, nog steeds zijn niet alle risicofactoren bekend en is er 
noodzaak om onderzoek te verrichten naar nieuwe risicofactoren. Hierbij richt men 
zich zowel op omgevingsfactoren als op genetische factoren. Beiden worden in dit 
proefschrift onderzocht. Hoofdstuk 1 is de algemene inleiding van dit 
proefschrift. Hierin wordt een overzicht gegeven over de huidige kennis van 
ADAMTS13 en VWF en de pathogenese bij arteriële trombose.
In Hoofdstuk 2 onderzochten wij of  ADAMTS13 een rol speelt in arteriële 
trombose. Wij onderzochten in hoofdstuk twee 124 patienten met een hersen-
infarct en 125 gezonde controles uit de COCOS studie. Hierbij werd gekeken 
naar de relatie tussen de plasmaspiegels van ADAMTS13 en VWF, de genetische 
variatie in het ADAMTS13 gen en het voorkomen van arteriële trombose. Wij 
vonden dat de plasmaspiegels van VWF significant hoger waren bij patienten 
ten opzichte van gezonde controles. Ook de hoeveelheden VWF antigeen en 
VWF activiteit waren geassocieerd met een hoger risico op arteriële trombose. 
(OR 3.2, 95%CI 1.4-7.5 and OR 2.1, 95%CI 0.9-4.8, respectievelijk) (Q1 vs 
Q4). De associatie tussen VWF en arteriële trombose werd niet beinvloed door 
ontsteking (concentratie-reactief  protein), ADAMTS13 of  door genetische 
variatie in het ADAMTS13 gen. De resultaten van deze studie zijn terug te lezen 
in hoofdstuk 2.
Een tweede studie, de ATTAC studie (hoofdstuk 3), werd uitgevoerd om nog 
uitvoeriger de rol van ADAMTS13, genetica en het voorkomen van arteriële 
trombose te bestuderen. De studie bevat 374 jonge patienten met hart- of  
herseninfarct of  perifeer vaatlijden en 332 gezonde controles. De mannen 
werden geincludeerd indien zij 45 jaar of  jonger waren, de vrouwen in deze 
studie konden worden geincludeerd, als zij 55 jaar of  jonger waren. De 
plasmaspiegels van ADAMTS13 waren sterk geassocieerd met het risico op 
arteri ële trombose OR 5.1 (95% CI, 3.1-8.5) (Q4 vs Q1). Ook de plasmaspiegels 
van VWF waren geassocieerd met het risico op arteriële trombose OR 2.1 
(95%CI 1.3-3.3) (Q1 vs Q4). Daarentegen, lieten de vier bestudeerde SNPs 
in het ADAMTS13 gen niet een duidelijke relatie met de plasmaspiegels van 
ADAMTS13 zien.
In hoofdstuk 4 onderzochten wij de rol van twee polymorfismen in het 
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ADAMTS13 en in het VWF gen. Het eerste polymorfisme, P475S, in het 
ADAMTS13 gen, veroorzaakt een substitutie van C1423 naar een T in exon 12. 
Van dit polymorfisme is bekend dat het de activiteit van ADAMTS13 kan 
beinvloeden. Wij onderzochten het P475S polymorfisme in de COCOS studie. 
Het minor allel van dit polymorfisme bleek niet voor te komen bij Caucasiërs. 
Wij concludeerden dat het P475S polymorfisme geen belangrijke bijdrage 
levert aan het risico op een herseninfarct in Caucasiërs. Tevens onderzochten wij 
dit polymorfisme in een groep van Chinezen en Afro-americanen. Het minor 
allel van dit polymorfisme kwam in 0.5% bij de Chinezen en in 0% van Afro- 
americanen voor. Onze data suggereert dat dit polymorfisme waarschijnlijk 
alleen een rol speelt in Japanners, gezien het feit dat in onze populaties de 
frequentie van het minor allel zeer laag is.
Het tweede polymorfisme dat is bestudeerd, Tyr1584Cys, bevindt zich in het 
VWF gen in exon 28. Dit polymorfisme is in de literatuur geassocieerd met een 
verhoogde proteolyse van VWF. Een verhoogde proteolyse van VWF zorgt voor 
de afbraak van ULVWF multimeren en voorkomt zo dat VWF groot blijft en 
zo spontaan bloedplaatjes kan aggregeren en daarmee een trombus vormt. Wij 
onderzochten dit polymorfisme in relatie tot arteriële trombose in twee studies 
(COCOS en ATTAC) naar arteriële trombose. De frequentie van het minor allel 
was 0.5-0.8% in de patienten en 0.6-3.2% in de gezonde controles. Gezien deze 
lage frequentie was het niet mogelijk een schatting te maken van de bijdrage van 
dit polymorfisme aan het risico op arteriële trombose. Wij concludeerden wel uit 
onze data dat het Tyr1584Cys polymorfisme geen belangrijke bijdrage levert aan 
het risico op arteriële trombose.
Het doel van hoofstuk 5 was om de rol van ADAMTS13 te bestuderen in 
pathologische condities anders dan cardiovasculaire ziekten. In patienten met 
sepsis worden vaak trombotische complicaties gezien. Vandaar dat wij de 
plasmaspiegels van ADAMTS13 in kinderen met meningococcen sepsis 
bestudeerden (hoofdstuk 5) . De plasmaspiegels van ADAMTS13 activiteit 
en antigeen bleken gedurende een periode van meningococcen sepsis sterk 
gereduceerd te  zijn (23.4% en 33.7% t.o.v. normaal, respectievelijk). Verlaagde 
plasmaspiegels van ADAMTS13 (rs = -0.38) en verhoogde plasmaspiegels van 
VWF (rs=-.050) waren geassocieerd met een slechtere uitkomstmaat, uitgedrukt 
in de PRISM score (pediatric risk of  mortality). Onze studie laat duidelijk zien 
dat in de acute fase van ernstige sepsis de plasmaspiegels van ADAMTS13 fors 
verlaagd zijn. 
In hoofdstuk 6 onderzochten we de rol van ADAMTS13 in patienten met 
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levercirrose. Levercirrose gaat gepaard met allerlei veranderingen in het 
hemostatische systeem. Vele verandering leiden tot een verminderde 
hemostatische capaciteit, maar er worden ook compensatoire mechanismen 
gevonden, zoals verhoogde VWF plasmaspiegels. ADAMTS13  wordt in de 
lever gemaakt en is het belangrijkste enzym dat VWF afbreekt. Daarom onder-
zochten wij de relatie tussen VWF en ADAMTS13 in lever cirrose patienten. 
De plasmaspiegels van VWF waren significant hoger in patienten met lever 
cirrose vergeleken met gezonde controles (Child A 380%, Child B 500%, en 
Child C 760% versus 107% in controles). VWF antigeen plasmaspiegels waren 
sterk gecorreleerd met de ernst van de cirrose, bepaald met de MELD score. 
De MELD score is een score voor de mate van eind-stadium lever cirrose. 
Ook VWF ristocetine activiteit was verhoogd bij patienten met cirrose, maar 
niet in dezelfde mate als de VWF antigeen plasmaspiegels. Dit houdt in dat de 
hoeveelheid VWF substantieel is verhoogd, maar dat het minder 
functioneel lijkt, wat betreft de binding van glycoproteine-Ib. De plasmaspiegels 
van ADAMTS13 in alle patienten lieten een grote variabiliteit zien, varierend van 
0.19 tot 3 U/ml. Het multimeer patroon van VWF was verlaagd ten opzichte van 
gezonde controles. De proportie hoog-moleculair-gewichts-multimeren was in 
Child A 63%, Child B 66%, en Child C 58% vergeleken met controles 73%. De 
propeptide plasmaspiegels van VWF waren verhoogd in alle patienten met lever 
cirrose (Child A 488%, Child B 711%, Child C 735% vergeleken met controles 
89%).
In hoofdstuk 7 worden de verschillende assays voor het meten van ADAMTS13 
activiteit en antigeen beschreven. Een grote variatie werd gezien tussen de 
verschillende assays. We vergeleken de plasmaspiegels van ADAMTS13 in 
controles, TTP patienten en patienten met lever cirrose. 
We concludeerden dat voor het identificeren van TTP patienten elke assay 
geschikt is, maar dat patienten met levercirrose meer onderzoek zal moeten 
worden gedaan om te bepalen wat de meest geschikt assay is.
In hoofdstuk 8 worden tenslotte onze bevindingen bediscussieerd en 
beschouwd in een groter geheel. Uit de resultaten van de verschillende 
onderzoeken, concluderen wij dat ADAMTS13 een belangrijke rol speelt bij 
arteriële trombose en een verhoogd risico geeft op arteriële trombose. Dit is 
met name gezien in patienten met coronair hart ziekten. Dit is bevestigd in 
meerdere onafhankelijke case-control studies. Echter, al deze studies waren case-
control studies en de resultaten moeten verder onderzocht worden in prospectieve 
studies. Tevens bevat dit hoofdstuk aanbevelingen voor toekomstig onderzoek.
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Na de vele proefschriften die voorbij kwamen, is het dan nu eindelijk ook zover: 
ik mag eindelijk het dankwoord gaan schrijven. Terugkijkend op de afgelopen 
jaren, besef  ik mij opeens dat dit promotieonderzoek een groot avontuur is 
geweest. Een reis door de jaren waarbij ik vele mensen heb leren kennen, 
uitdagingen heb getrotseerd en vriendschappen heb gesloten. Dit onder-
zoek was natuurlijk niet mogelijk geweest zonder de steun van patienten, 
familieleden, vrienden en collega’s. Zonder hen was het niet mogelijk geweest dit 
promotieonderzoek tot een goed einde te brengen. Mijn dank hiervoor is groot. 
Enkele mensen wie ik graag persoonlijk noemen, waarbij ik me realiseer nooit 
volledig te kunnen zijn. Ik hoop dan ook dat de mensen die ik hier oversla, weten 
dat ik ze minstens zoveel dank verschuldigd ben.
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Mijn promotor prof. dr. F.W.G. Leebeek, beste Frank. Ik leerde je kennen via 
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zoekje aan de Christopher studie was je degene die kwam met een leuk voorstel 
voor een nogal ambitieus keuzeonderzoek. Dit bleek later de basis te zijn voor 
dit proefschrift. Bedankt voor het gestelde vertrouwen en je geduld. Eindelijk nu 
een volmondig JA, het is af! Het is bewonderenswaardig hoe jij wetenschappelijk 
onderzoek en kliniek kunt combineren. Tevens bedankt voor alle keren dat je uit 
het blote hoofd de artikelen met journal en jaartal kon opnoemen welke ik niet 
meer terug kon vinden! Ik wens je al het beste toe.
Dr M.P.M. de Maat, beste Moniek. Jij was mijn directe aanspreekpunt op de 
afdeling Hematologie en wat wist ik je te vinden. Je stond altijd voor me klaar 
met tips, adviezen en met je correcties op artikelen, abstract en presentaties. 
Zelf  in Sydney, toen ik zonder stem aankwam, heb je ervoor gezorgd dat ik op 
tijd weer “fit” was. Tevens bewonder ik je enorme kennis van programma’s, met 
in het bijzonder SPSS. Bedankt dat je altijd bereikbaar was, telefonisch of  in de 
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Dit was met name erg prettig gedurende mijn “vrije”momenten in mijn coschap-
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sparring partner te hebben. Je immer kritisch blik kwam vaak van pas! Bedankt 
voor alle keren dat ik weer eens de behoefte had om mijn frustaties te ventileren 
en bedankt als luisterend oor. Je ging samen met Ana en mij het Australische 
avontuur aan (Victoria Building, kangaroo/cranberry, turbulentie).  En dat was 
slechts een van de vele congresreizen die we samen beleefden. Bedankt dat je 
samen met mij in Duitsland uit de dip wilde komen. Wat hebben we daar hard 
gewerkt, maar wat was het leuk! Ik ben erg blij dat je mijn paranimf  wilde zijn en 
hoop dat we nog lang vrienden zullen blijven. Ik wens jou, je ouders en Annelies 
het allerbeste!
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snel weer bij een borrel of  een lekker etentje. Ik wens jou, Winfried en Ella alle 
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